Advertisement

Cellular and Molecular Neurobiology

, Volume 39, Issue 1, pp 31–59 | Cite as

Dopamine: Functions, Signaling, and Association with Neurological Diseases

  • Marianne O. Klein
  • Daniella S. Battagello
  • Ariel R. Cardoso
  • David N. Hauser
  • Jackson C. BittencourtEmail author
  • Ricardo G. CorreaEmail author
Review Paper

Abstract

The dopaminergic system plays important roles in neuromodulation, such as motor control, motivation, reward, cognitive function, maternal, and reproductive behaviors. Dopamine is a neurotransmitter, synthesized in both central nervous system and the periphery, that exerts its actions upon binding to G protein-coupled receptors. Dopamine receptors are widely expressed in the body and function in both the peripheral and the central nervous systems. Dopaminergic signaling pathways are crucial to the maintenance of physiological processes and an unbalanced activity may lead to dysfunctions that are related to neurodegenerative diseases. Unveiling the neurobiology and the molecular mechanisms that underlie these illnesses may contribute to the development of new therapies that could promote a better quality of life for patients worldwide. In this review, we summarize the aspects of dopamine as a catecholaminergic neurotransmitter and discuss dopamine signaling pathways elicited through dopamine receptor activation in normal brain function. Furthermore, we describe the potential involvement of these signaling pathways in evoking the onset and progression of some diseases in the nervous system, such as Parkinson’s, Schizophrenia, Huntington’s, Attention Deficit and Hyperactivity Disorder, and Addiction. A brief description of new dopaminergic drugs recently approved and under development treatments for these ailments is also provided.

Keywords

Dopamine pathway Neurotransmitter Central nervous system Neurodegenerative diseases 

Abbreviations

AD

Alzheimer’s disease

ADHD

Attention deficit/hyperactivity disorder

ALDH

Aldehyde dehydrogenase

BDNF

Brain-derived neurotropic factor

CaMKII

Calcium/calmodulin-dependent kinase II

cAMP

Cyclic 3,5 adenine-monophosphate

CDK5

Cyclin-dependent kinase 5

CK1

Casein kinase 1

CK2

Casein kinase 2

COMT

Catechol-O-methyl transferase

CREB

cAMP Response element-binding protein

CSF

Cerebral spinal fluid

DAG

Diacylglycerol

DARPP-32

cAMP-Regulated phosphoprotein 32-kDa

DAT

Dopamine transporter

DJ-1

PARK7 (Parkinson disease protein 7)

DOPAC

3,4-Dihydroxyphenylacetic acid

DOPAL

3,4-Dihydroxyphenylaldehyde

ELKs

Glutamine, leucine, lysine, and serine-rich protein

ERK

Extracellular-signal regulated kinases

FDA

US Food and Drug Administration

GABA

γ-Amino butyric acid

GIRK

G protein inwardly rectifying potassium channel

GPCR

G protein-coupled receptor

GRK

G protein-coupled receptor kinase

GSK3

Glycogen synthase kinase 3

GSTM2

Glutathione transferase

GTP

Guanosine triphosphate

HVA

Homovanillic acid

HD

Huntington’s disease

HTT

Huntingtin gene

IGF

Insulin growth factor

IP3

Inositol trisphosphate

JNK

c-Jun kinase

L-DOPA

Levodopa

LB

Lewy bodies

LRRK2

Leucine-rich repeat kinase 2

MAPK

Mitogen-activated protein kinase

MAPT

Microtubule-associated protein

MAT

Monoamine transporter

MAO

Monoamine oxidase

mTORC2

mTOR complex 2

NAc

Nucleus accumbens

NET

Norepinephrine transporter

NMDA

Glutamate N-methyl-d-aspartate

Parkin

PRKN

PD

Parkinson’s disease

PDPK1

Phosphatidylinositol-dependent kinase 1

PIP2

Phosphatidylinositol-2-phosphate

PIP3

Phosphatidylinositol-3-phosphate

PKA

Protein kinase A

PKC

Protein kinase C

PLC

Phospholipase C

PP1

Protein phosphatase 1

PP2A

Protein phosphatase 2A

PP2B

Protein phosphatase 2B

RGS

Regulators of G protein signaling

RIM

Rab3a-interacting molecule

ROS

Reactive oxygen species

RTK

Receptor tyrosine kinase

SNCA

α-Synuclein

STEP

Striatal-enriched tyrosine phosphatase

SZ

Schizophrenia

TAAR

Trace amine-associated receptors

VMAT2

Vesicular monoamine transporter

VTA

Ventral tegmental area

Notes

Acknowledgements

This review was supported by São Paulo State Foundation for the Support of Research (FAPESP, Brazil; Grant #2016/02224-1 to JCB, Grant #2017/17998-5 to MOK, and Grant #2017/18019-0 to ARC). DSB is a fellowship recipient of the Agency for the Advancement of Higher Education (CAPES, Brazil). JCB is a recipient of grants from the National Council for Scientific and Technological Development (CNPq, Brazil; Grant #426378/2016-4), CAPES, and the Comité Français d’Evaluation de la Coopération Universitaire avec le Brésil (French Committee for the Evaluation of Academic and Scientific Cooperation with Brazil; CAPES-COFECUB Grant #848/15). RGC was partially supported by a Special Visiting Researcher (PVE) grant from the “Science without Borders” Program (CAPES).

Author Contributions

In this review, all authors had full access to the data and take all responsibility for its integrity and accuracy. MOK, DSB, and ARC drafted the manuscript, under supervision of JCB and RGC. MOK and DSB conceptualized and designed the figures. DNH, JCB, and RGC made critical revisions of the manuscript for their relevant intellectual content. JCB and RGC obtained the funding. All authors read and approved the final manuscript.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Agnati LF, Zoli M, Strömberg I, Fuxe K (1995) Intercellular communication in the brain: wiring versus volume transmission. Neuroscience 69:711–726CrossRefPubMedGoogle Scholar
  2. Aguayo LG, Grossie J (1994) Dopamine inhibits a sustained calcium current through activation of alpha adrenergic receptors and a GTP-binding protein in adult rat sympathetic neurons. J Pharmacol Exp Ther 269:503–508PubMedGoogle Scholar
  3. Aguirre P, Urrutia P, Tapia V et al (2012) The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1. Biometals 25:795–803CrossRefPubMedGoogle Scholar
  4. Altar CA, Hunt RA, Jurata LW et al (2008) Insulin, IGF-1, and muscarinic agonists modulate schizophrenia-associated genes in human neuroblastoma cells. Biol Psychiatry 64:1077–1087.  https://doi.org/10.1016/j.biopsych.2008.08.031 CrossRefPubMedGoogle Scholar
  5. Andén N-E, Corrodi H, Dahlström A et al (1966) Effects of tyrosine hydroxylase inhibition on the amine levels of central monoamine neurons. Life Sci 5:561–568CrossRefGoogle Scholar
  6. Andretic R, van Swinderen B, Greenspan RJ (2005) Dopaminergic modulation of arousal in Drosophila. Curr Biol 15:1165–1175CrossRefPubMedGoogle Scholar
  7. Andrews ZB, Kokay IC, Grattan DR (2001) Dissociation of prolactin secretion from tuberoinfundibular dopamine activity in late pregnant rats. Endocrinology 142:2719–2724.  https://doi.org/10.1210/endo.142.6.8196 CrossRefPubMedGoogle Scholar
  8. Angers S, Salahpour A, Bouvier M (2002) Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol 42:409–435.  https://doi.org/10.1146/annurev.pharmtox.42.091701.082314 CrossRefPubMedGoogle Scholar
  9. Anlauf M, Schäfer MKH, Eiden L, Weihe E (2003) Chemical coding of the human gastrointestinal nervous system: Cholinergic, VIPergic, and catecholaminergic phenotypes. J Comp Neurol 459:90–111.  https://doi.org/10.1002/cne.10599 CrossRefPubMedGoogle Scholar
  10. Aosaki T, Kiuchi K, Kawaguchi Y (1998) Dopamine D1-like receptor activation excites rat striatal large aspiny neurons in vitro. J Neurosci 18:5180–5190CrossRefPubMedGoogle Scholar
  11. Aperia AC (2000) Intrarenal dopamine: a key signal in the interactive regulation of sodium metabolism. Annu Rev Physiol 62:621–647CrossRefPubMedGoogle Scholar
  12. Arbogast LA, Voogt JL (1996) The responsiveness of tuberoinfundibular dopaminergic neurons to prolactin feedback is diminished between early lactation and midlactation in the rat. Endocrinology 137:47–54.  https://doi.org/10.1210/endo.137.1.8536641 CrossRefPubMedGoogle Scholar
  13. Arnsten AF, Dudley AG (2005) Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behav brain Funct 1:2.  https://doi.org/10.1186/1744-9081-1-2 CrossRefPubMedPubMedCentralGoogle Scholar
  14. Arnt J, Scheel-Krüger J (1979) GABA in the ventral tegmental area: differential regional effects on locomotion, aggression and food intake after microinjection of GABA agonists and antagonists. Life Sci 25:1351–1360CrossRefPubMedGoogle Scholar
  15. Arriagada C, Paris I, de las Matas MJS et al (2004) On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: mitochondria damage, necrosis, and hydroxyl radical formation. Neurobiol Dis 16:468–477CrossRefPubMedGoogle Scholar
  16. Arriza JL, Dawson TM, Simerly RB et al (1992) The G-protein-coupled receptor kinases beta ARK1 and beta ARK2 are widely distributed at synapses in rat brain. J Neurosci 12:4045–4055CrossRefPubMedGoogle Scholar
  17. Asif-Malik A, Hoener MC, Canales JJ (2017) Interaction between the trace amine-associated receptor 1 and the dopamine D2 receptor controls cocaine’s neurochemical actions. Sci Rep 7:13901CrossRefPubMedPubMedCentralGoogle Scholar
  18. Aston-Jones G (2005) Brain structures and receptors involved in alertness. Sleep Med 6:S3–S7CrossRefPubMedGoogle Scholar
  19. Attwell D, Barbour B, Szatkowski M (1993) Nonvesicular release of neurotransmitter. Neuron 11:401–407CrossRefPubMedGoogle Scholar
  20. Baik J-H (2013a) Dopamine Signaling in reward-related behaviors. Front Neural Circuits 7:1–16.  https://doi.org/10.3389/fncir.2013.00152 CrossRefGoogle Scholar
  21. Baik J-H (2013b) Dopamine signaling in food addiction: role of dopamine D2 receptors. BMB Rep 46:519CrossRefPubMedPubMedCentralGoogle Scholar
  22. Baracskay KL, Haroutunian V, Meador-Woodruff JH (2006) Dopamine receptor signaling molecules are altered in elderly schizophrenic cortex. Synapse 60:271–279CrossRefPubMedGoogle Scholar
  23. Bara-Jimenez W, Aksu M, Graham B et al (2000) Periodic limb movements in sleep state-dependent excitability of the spinal flexor reflex. Neurology 54:1609–1616CrossRefPubMedGoogle Scholar
  24. Bardo MT, Donohew RL, Harrington NG (1996) Psychobiology of novelty seeking and drug seeking behavior. Behav Brain Res 77:23–43CrossRefPubMedGoogle Scholar
  25. Barker RA, Parmar M, Studer L, Takahashi J (2017) Human trials of stem cell-derived dopamine neurons for Parkinson’s disease: dawn of a new era. Cell Stem Cell 21:569–573.  https://doi.org/10.1016/j.stem.2017.09.014 CrossRefGoogle Scholar
  26. Barraud Q, Obeid I, Aubert I et al (2010) Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primate. PLoS ONE 5:e13306CrossRefPubMedPubMedCentralGoogle Scholar
  27. Bartfai T, Iverfeldt K, Fisone G, Serfozo P (1988) Regulation of the release of coexisting neurotransmitters. Annu Rev Pharmacol Toxicol 28:285–310CrossRefPubMedGoogle Scholar
  28. Basu S, Dasgupta PS (2000) Dopamine, a neurotransmitter, influences the immune system. J Neuroimmunol 102:113–124CrossRefPubMedGoogle Scholar
  29. Bateup HS, Svenningsson P, Kuroiwa M et al (2008) Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci 11:932–939.  https://doi.org/10.1038/nn.2153 CrossRefPubMedPubMedCentralGoogle Scholar
  30. Beaulieu J-M (2011) Beyond cAMP: the regulation of Akt and GSK3 by dopamine receptors. Front Mol Neurosci 4:1–13.  https://doi.org/10.3389/fnmol.2011.00038 CrossRefGoogle Scholar
  31. Beaulieu J-M, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63:182–217CrossRefPubMedGoogle Scholar
  32. Beaulieu J-M, Sotnikova TD, Yao W-D et al (2004) Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci 101:5099–5104.  https://doi.org/10.1073/pnas.0307921101 CrossRefPubMedGoogle Scholar
  33. Beaulieu JM, Sotnikova TD, Marion S et al (2005) An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261–273.  https://doi.org/10.1016/j.cell.2005.05.012 CrossRefPubMedGoogle Scholar
  34. Beaulieu J-M, Tirotta E, Sotnikova TD et al (2007) Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci 27:881–885.  https://doi.org/10.1523/JNEUROSCI.5074-06.2007 CrossRefPubMedGoogle Scholar
  35. Beaulieu J-M, Gainetdinov RR, Caron MG (2009) Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49:327–347.  https://doi.org/10.1146/annurev.pharmtox.011008.145634 CrossRefGoogle Scholar
  36. Beaulieu JM, Espinoza S, Gainetdinov RR (2015) Dopamine receptors—IUPHAR review 13. Br J Pharmacol 172:1–23.  https://doi.org/10.1111/bph.12906 CrossRefPubMedGoogle Scholar
  37. Beilina A, Cookson MR (2016) Genes associated with Parkinson’s disease: regulation of autophagy and beyond. J Neurochem 139 Suppl:91–107.  https://doi.org/10.1111/jnc.13266 CrossRefGoogle Scholar
  38. Ben-Jonathan N, Hnasko R (2001) Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22:724–763.  https://doi.org/10.1210/edrv.22.6.0451 CrossRefPubMedGoogle Scholar
  39. Beom S, Cheong D, Torres G et al (2004) Comparative studies of molecular mechanisms of dopamine D2 and D3 receptors for the activation of extracellular signal-regulated kinase. J Biol Chem 279:28304–28314.  https://doi.org/10.1074/jbc.M403899200 CrossRefPubMedGoogle Scholar
  40. Berman DM, Gilman AG (1998) Mammalian RGS proteins: barbarians at the gate. J Biol Chem 273:1269–1272.  https://doi.org/10.1074/jbc.273.3.1269 CrossRefPubMedGoogle Scholar
  41. Berridge MJ (2009) Inositol trisphosphate and calcium signalling mechanisms. Biochim Biophys Acta 1793:933–940.  https://doi.org/10.1016/j.bbamcr.2008.10.005 CrossRefPubMedGoogle Scholar
  42. Berridge MJ (2016) The inositol trisphosphate/calcium signaling pathway in health and disease. Physiol Rev 96:1261–1296.  https://doi.org/10.1152/physrev.00006.2016 CrossRefPubMedGoogle Scholar
  43. Berridge KC, Kringelbach ML (2008) Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacology 199:457–480CrossRefPubMedPubMedCentralGoogle Scholar
  44. Bertorello AM, Hopfield JF, Aperia A, Greengard P (1990) Inhibition by dopamine of (Na(+) + K+)ATPase activity in neostriatal neurons through D1 and D2 dopamine receptor synergism. Nature 347:386–388.  https://doi.org/10.1038/347386a0 CrossRefPubMedGoogle Scholar
  45. Bibb JA, Snyder GL, Nishi A et al (1999) Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402:669–671.  https://doi.org/10.1038/45251 CrossRefPubMedGoogle Scholar
  46. Biederman J (2005) Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 57:1215–1220CrossRefPubMedGoogle Scholar
  47. Bilder RM, Volavka J, Lachman HM, Grace AA (2004) The catechol-O-methyltransferase polymorphism: Relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 29:1943–1961.  https://doi.org/10.1038/sj.npp.1300542 CrossRefPubMedGoogle Scholar
  48. Bjo A, Lindvall O, Nobin A et al (1975) Evidence of an incerto-hypothalamic dopamine neurone system in the rat. Brain Res 89:29–42CrossRefGoogle Scholar
  49. Borowsky B, Adham N, Jones KA et al (2001) Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci 98:8966–8971CrossRefPubMedGoogle Scholar
  50. Bozzi Y, Borrelli E (2006) Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it? Trends Neurosci 29:167–174CrossRefPubMedGoogle Scholar
  51. Bromek E, Haduch A, Gołembiowska K, Daniel WA (2011) Cytochrome P450 mediates dopamine formation in the brain in vivo. J Neurochem 118:806–815CrossRefPubMedGoogle Scholar
  52. Brown GM, Krigstein E, Dankova J, Hornykiewicz O (1972) Relationship between hypothalamic and median eminence catecholamines and thyroid function. Neuroendocrinology 10:207–217CrossRefPubMedGoogle Scholar
  53. Buckholtz JW, Treadway MT, Cowan RL et al (2010) Dopaminergic network differences in human impulsivity. Science 329:532CrossRefPubMedPubMedCentralGoogle Scholar
  54. Burchett S (2000) Regulators of G protein signaling: a bestiary of modular protein binding domains [In Process Citation]. J Neurochem 75:1335–1351CrossRefPubMedGoogle Scholar
  55. Burt DR, Enna SJ, Creese I, Snyder SH (1975) Dopamine receptor binding in the corpus striatum of mammalian brain. Proc Natl Acad Sci U S A 72:4655–4659.  https://doi.org/10.1073/pnas.72.11.4655 CrossRefPubMedPubMedCentralGoogle Scholar
  56. Bychkov E, Zurkovsky L, Garret MB et al (2012) Distinct cellular and subcellular distributions of G protein-coupled receptor kinase and arrestin isoforms in the striatum. PLoS ONE 7:e48912.  https://doi.org/10.1371/journal.pone.0048912 CrossRefPubMedPubMedCentralGoogle Scholar
  57. Cachope R, Cheer JF (2014) Local control of striatal dopamine release. Front Behav Neurosci 8:188CrossRefPubMedPubMedCentralGoogle Scholar
  58. Cahill E, Salery M, Vanhoutte P, Caboche J (2014) Convergence of dopamine and glutamate signaling onto striatal ERK activation in response to drugs of abuse. Front Pharmacol 4 JAN:1–13.  https://doi.org/10.3389/fphar.2013.00172 CrossRefGoogle Scholar
  59. Calabresi P, Centonze D, Bernardi G (2000) Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci 23:S57–S63CrossRefPubMedGoogle Scholar
  60. Calabresi P, Picconi B, Tozzi A et al (2014) Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci 17:1022CrossRefPubMedGoogle Scholar
  61. Carboni E, Silvagni A (2004) Dopamine reuptake by norepinephrine neurons: exception or rule? Crit Rev Neurobiol 16Google Scholar
  62. Carboni E, Silvagni A, Vacca C, Di Chiara G (2006) Cumulative effect of norepinephrine and dopamine carrier blockade on extracellular dopamine increase in the nucleus accumbens shell, bed nucleus of stria terminalis and prefrontal cortex. J Neurochem 96:473–481CrossRefPubMedGoogle Scholar
  63. Cardinal RN, Pennicott DR, Lakmali C et al (2001) Impulsive choice induced in rats by lesions of the nucleus accumbens core. Science 292:2499–2501CrossRefPubMedGoogle Scholar
  64. Carlezon WA Jr, Thomas MJ (2009) Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis. Neuropharmacology 56:122–132CrossRefPubMedGoogle Scholar
  65. Carli M, Evenden JL, Robbins TW (1985) Depletion of unilateral striatal dopamine impairs initiation of contralateral actions and not sensory attention. Nature 313:679CrossRefPubMedGoogle Scholar
  66. Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson’s disease. Trends Neurosci 13:272–276CrossRefPubMedGoogle Scholar
  67. Carlsson A, Lindqvist M, Magnusson TOR (1957) 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200CrossRefPubMedGoogle Scholar
  68. Carman CV, Benovic JL (1998) G-protein-coupled receptors: turn-ons and turn-offs. Curr Opin Neurobiol 8:335–344.  https://doi.org/10.1016/S0959-4388(98)80058-5 CrossRefPubMedGoogle Scholar
  69. Carrick WT, Burks B, Cairns MJ, Kocerha J (2016) Noncoding RNA regulation of dopamine signaling in diseases of the central nervous system. Front Mol Biosci 3:1–8.  https://doi.org/10.3389/fmolb.2016.00069 CrossRefGoogle Scholar
  70. Castellanos FX, Tannock R (2002) Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci 3:617.  https://doi.org/10.1038/nrn896 CrossRefPubMedGoogle Scholar
  71. Castle DJ, Murray RM (1991) The neurodevelopmental basis of sex differences in schizophrenia. Psychol Med 21:565–575CrossRefPubMedGoogle Scholar
  72. Celver J, Sharma M, Kovoor A (2010) RGS9-2 mediates specific inhibition of agonist-induced internalization of D2-dopamine receptors. J Neurochem 114:739–749.  https://doi.org/10.1111/j.1471-4159.2010.06805.x CrossRefPubMedGoogle Scholar
  73. Cenci MA (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30:236–243CrossRefPubMedGoogle Scholar
  74. Cepeda C, Murphy KPS, Parent M, Levine MS (2014) The role of dopamine in Huntington’s disease. Prog Brain Res 211:235–254CrossRefPubMedPubMedCentralGoogle Scholar
  75. Champagne F, Chretien P, Stevenson C et al (2004) Variations in nucleus accumbens dopamine associated with individual differences in maternal behavior in the rat. J Neurosci 24:4113–4123.  https://doi.org/10.1523/JNEUROSCI.5322-03.2004 CrossRefPubMedGoogle Scholar
  76. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410:37–40.  https://doi.org/10.1038/35065000 CrossRefPubMedGoogle Scholar
  77. Chang D, Nalls MA, Hallgrimsdottir IB et al (2017) A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk loci. Nat Genet 49:1511–1516.  https://doi.org/10.1038/ng.3955 CrossRefPubMedPubMedCentralGoogle Scholar
  78. Chasse SA, Dohlman HG (2003) RGS proteins: G protein-coupled receptors meet their match. Assay Drug Dev Technol 1:357–364.  https://doi.org/10.1089/154065803764958649 CrossRefPubMedGoogle Scholar
  79. Chen J, Rusnak M, Luedtke RR, Sidhu A (2004) D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. J Biol Chem 279:39317–39330.  https://doi.org/10.1074/jbc.M403891200 CrossRefPubMedGoogle Scholar
  80. Chen J, Song J, Yuan P et al (2011) Orientation and cellular distribution of membrane-bound catechol-O-methyltransferase in cortical neurons: implications for drug development. J Biol Chem 286:34752–34760CrossRefPubMedPubMedCentralGoogle Scholar
  81. Cheng H, Ulane Christina M, Burke Robert E (2010) Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 67:715–725.  https://doi.org/10.1002/ana.21995 CrossRefPubMedPubMedCentralGoogle Scholar
  82. Chio CL, Lajiness ME, Huff RM (1994) Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol Pharmacol 45:51–60PubMedGoogle Scholar
  83. Choi EY, Jeong D, Park KW, Baik JH (1999) G protein-mediated mitogen-activated protein kinase activation by two dopamine D2 receptors. Biochem Biophys Res Commun 256:33–40CrossRefPubMedGoogle Scholar
  84. Christenson JG, Dairman W, Udenfriend S (1970) Preparation and properties of a homogeneous aromatic l-amino acid decarboxylase from hog kidney. Arch Biochem Biophys 141:356–367CrossRefPubMedGoogle Scholar
  85. Chrousos GP (2009) Stress and disorders of the stress system. Nat Rev Endocrinol 5:374CrossRefPubMedGoogle Scholar
  86. Citrome L (2013) A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs 27:879–911.  https://doi.org/10.1007/s40263-013-0105-7 CrossRefPubMedGoogle Scholar
  87. Citrome L (2015) Brexpiprazole: a new dopamine D2 receptor partial agonist for the treatment of schizophrenia and major depressive disorder. Drugs Today 51:397–414.  https://doi.org/10.1358/dot.2015.51.7.2358605 CrossRefPubMedGoogle Scholar
  88. Clemens S, Hochman S (2004) Conversion of the modulatory actions of dopamine on spinal reflexes from depression to facilitation in D3 receptor knock-out mice. J Neurosci 24:11337–11345CrossRefPubMedPubMedCentralGoogle Scholar
  89. Clemens S, Rye D, Hochman S (2006) Restless legs syndrome Revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 67:125–130CrossRefPubMedGoogle Scholar
  90. Cohen I, Todd RD, Harmon S, O’Malley KL (1992) Photoreceptors of mouse retinas possess D4 receptors coupled to adenylate cyclase. Proc Natl Acad Sci USA 89:12093–12097.  https://doi.org/10.1073/pnas.89.24.12093 CrossRefPubMedGoogle Scholar
  91. Colbran RJ, Brown AM (2004) Calcium/calmodulin-dependent protein kinase II and synaptic plasticity. Curr Opin Neurobiol 14:318–327.  https://doi.org/10.1016/j.conb.2004.05.008 CrossRefPubMedGoogle Scholar
  92. Contreras F, Fouillioux C, Bol\’\ivar A et al (2002) Dopamine, hypertension and obesity. J Hum Hypertens 16:S13CrossRefPubMedGoogle Scholar
  93. Cornil CA, Balthazart J, Motte P et al (2002) Dopamine activates noradrenergic receptors in the preoptic area. J Neurosci 22:9320–9330CrossRefPubMedPubMedCentralGoogle Scholar
  94. Cornil CA, Castelino CB, Ball GF (2008) Dopamine binds to alpha2-adrenergic receptors in the song control system of zebra finches (Taeniopygia guttata). J Chem Neuroanat 35:202–215CrossRefPubMedGoogle Scholar
  95. Cross D, Alessi DR, Cohen P et al (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785–789.  https://doi.org/10.1038/378785a0 CrossRefGoogle Scholar
  96. Crowley WR (2015) Neuroendocrine regulation of lactation and milk production. Compr Physiol 5:255–291.  https://doi.org/10.1002/cphy.c140029 CrossRefPubMedGoogle Scholar
  97. Cunha-Filho JS, Gross JL, Lemos NA et al (2002) Prolactin and growth hormone secretion after thyrotrophin-releasing hormone infusion and dopaminergic (DA2) blockade in infertile patients with minimal/mild endometriosis. Hum Reprod 17:960–965CrossRefPubMedGoogle Scholar
  98. Cyr M, Sotnikova TD, Gainetdinov RR, Caron MG (2006) Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin. FASEB J 20:2541–2543CrossRefPubMedGoogle Scholar
  99. Dahlström A, Fuxe K (1964) A method for the demonstration of monoamine-containing nerve fibres in the central nervous system. Acta Physiol 60:293–294CrossRefGoogle Scholar
  100. Dal Toso R, Sommer B, Ewert M et al (1989) The dopamine D2 receptor: two molecular forms generated by alternative splicing. Embo J 8:4025–4034CrossRefPubMedPubMedCentralGoogle Scholar
  101. Dale H (1935) Pharmacology and nerve-endings: Walter Ernest Dixon Memorial Lecture. Proc R Soc Med 28:319–332PubMedPubMedCentralGoogle Scholar
  102. Dale H (1937) Transmission of nervous effects by acetylcholine: Harvey Lecture, May 20, 1937. Bull N Y Acad Med 13:379PubMedPubMedCentralGoogle Scholar
  103. Damier P, Kastner A, Agid Y, Hirsch EC (1996) Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson’s disease? Neurology 46:1262CrossRefPubMedGoogle Scholar
  104. Damsma G, Pfaus JG, Wenkstern D et al (1992) Sexual behavior increases dopamine transmission in the nucleus accumbens and striatum of male rats: comparison with novelty and locomotion. Behav Neurosci 106:181CrossRefPubMedGoogle Scholar
  105. Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909CrossRefPubMedGoogle Scholar
  106. De Deurwaerdère P (2016) Cariprazine: new dopamine biased agonist for neuropsychiatry disorders. Drugs of Today 52:97–110.  https://doi.org/10.1358/dot.2016.52.2.2461868 CrossRefPubMedGoogle Scholar
  107. De Mei C, Ramos M, Iitaka C, Borrelli E (2009) Getting specialized: presynaptic and postsynaptic dopamine D2 receptors. Curr Opin Pharmacol 9:53–58.  https://doi.org/10.1016/j.coph.2008.12.002 CrossRefPubMedPubMedCentralGoogle Scholar
  108. Demarest KT, McKay DW, Riegle GD, Moore KE (1983) Biochemical indices of tuberoinfundibular dopaminergic neuronal activity during lactation: a lack of response to prolactin. Neuroendocrinology 36:130–137CrossRefPubMedGoogle Scholar
  109. Demarest KT, Riegle GD, Moore KE (1984) Prolactin-induced activation of tuberoinfundibular dopaminergic neurons: evidence for both a rapid ‘tonic’ and a delayed ‘delayed’ component. Neuroendocrinology 38:467–475CrossRefPubMedGoogle Scholar
  110. Deming JD, Shin JA, Lim K et al (2015) Dopamine receptor D4 internalization requires a beta-arrestin and a visual arrestin. Cell Signal 27:2002–2013.  https://doi.org/10.1016/j.cellsig.2015.06.008 CrossRefPubMedGoogle Scholar
  111. Depue RA, Collins PF (1999) Neurobiology of the structure of personality: dopamine, facilitation of incentive motivation, and extraversion. Behav Brain Sci 22:491–517CrossRefPubMedGoogle Scholar
  112. Desdouits F, Siciliano JC, Greengard P, Girault JA (1995) Dopamine- and cAMP-regulated phosphoprotein DARPP-32: phosphorylation of Ser-137 by casein kinase I inhibits dephosphorylation of Thr-34 by calcineurin. Proc Natl Acad Sci 92:2682–2685.  https://doi.org/10.1073/pnas.92.7.2682 CrossRefPubMedGoogle Scholar
  113. Devoto P, Flore G (2006) On the origin of cortical dopamine: is it a co-transmitter in noradrenergic neurons? Curr Neuropharmacol 4:115–125CrossRefPubMedPubMedCentralGoogle Scholar
  114. Devoto P, Flore G, Saba P et al (2015) Selective inhibition of dopamine-beta-hydroxylase enhances dopamine release from noradrenergic terminals in the medial prefrontal cortex. Brain Behav 5:e00393CrossRefPubMedPubMedCentralGoogle Scholar
  115. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69:483–510.  https://doi.org/10.1146/annurev.ph.69.013107.100021 CrossRefPubMedGoogle Scholar
  116. Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62:132–144CrossRefPubMedGoogle Scholar
  117. Di GC, Tanda GL, Frau R, Carboni E (1992) Heterologous monoamine reuptake: lack of transmitter specificity of neuron-specific carriers. Neurochem Int 20:231S–235SGoogle Scholar
  118. Dickey AS, La Spada AR (2017) Therapy development in Huntington disease: from current strategies to emerging opportunities. Am J Med Genet Part A 176:842–861CrossRefPubMedGoogle Scholar
  119. Dingledine R, Borges K, Bowie D, Traynelis SF (1999) The glutamate receptor ion channels. Pharmacol Rev 51:7–62PubMedGoogle Scholar
  120. Doi M, Yujnovsky I, Hirayama J et al (2006) Impaired light masking in dopamine D2 receptor-null mice. Nat Neurosci 9:732–734.  https://doi.org/10.1038/nn1711 CrossRefPubMedGoogle Scholar
  121. Dolmetsch RE, Pajvani U, Fife K et al (2001) Signaling to the nucleus by an L-type calcium channel- calmodulin complex through the MAP kinase pathway. Science 294:333–339.  https://doi.org/10.1126/science.1063395 CrossRefPubMedGoogle Scholar
  122. Ebaugh FG (1923) Neuropsychiatric sequelae of acute epidemic encephalitis in children. Am J Dis Child 25:89–97Google Scholar
  123. Eiden LE, Weihe E (2011) VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Ann N Y Acad Sci 1216:86–98.  https://doi.org/10.1111/j.1749-6632.2010.05906.x CrossRefPubMedPubMedCentralGoogle Scholar
  124. Eiden LE, Schäfer MKH, Weihe E, Schütz B (2004) The vesicular amine transporter family (SLC18): Amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflugers Arch Eur J Physiol 447:636–640.  https://doi.org/10.1007/s00424-003-1100-5 CrossRefGoogle Scholar
  125. Eisenhofer G, Kopin IJ, Goldstein DS (2004) Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 56:331CrossRefPubMedGoogle Scholar
  126. Elliott TR (1905) The action of adrenalin. J Physiol 32:401–467CrossRefPubMedPubMedCentralGoogle Scholar
  127. Erdtmann-Vourliotis M, Mayer P, Ammon S et al (2001) Distribution of G-protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain. Brain Res Mol Brain Res 95:129–137.  https://doi.org/10.1016/S0006-8993(01)03046-3 CrossRefPubMedGoogle Scholar
  128. Espinoza S, Salahpour A, Masri B et al (2011) Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol Pharmacol 80:416–425CrossRefPubMedPubMedCentralGoogle Scholar
  129. Fallon JH, Moore RY (1978) Catecholamine innervation of the basal forebrain III. Olfactory bulb, anterior olfactory nuclei, olfactory tubercle and piriform cortex. J Comp Neurol 180:533–544CrossRefPubMedGoogle Scholar
  130. Fambrough DM, Drachman DB, Satyamurti S (1973) Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 182:293–295CrossRefPubMedGoogle Scholar
  131. Faraone SV, Sergeant J, Gillberg C, Biederman J (2003) The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2:104PubMedPubMedCentralGoogle Scholar
  132. Faraone SV, Perlis RH, Doyle AE et al (2005) Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1313–1323CrossRefPubMedGoogle Scholar
  133. Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114 (Pt 5:2283–2301CrossRefPubMedGoogle Scholar
  134. Felder CC, Jose PA, Axelrod J (1989) The dopamine-1 agonist, SKF 82526, stimulates phospholipase-C activity independent of adenylate cyclase. J Pharmacol Exp Ther 248:171–175PubMedGoogle Scholar
  135. Felicio AC, Shih MC, Godeiro-Junior C et al (2009) Molecular imaging studies in Parkinson disease: reducing diagnostic uncertainty. Neurologist 15:6–16CrossRefPubMedGoogle Scholar
  136. Ferguson SS (2001) Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53:1–24PubMedGoogle Scholar
  137. Ferguson CS, Tyndale RF (2011) Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends Pharmacol Sci 32:708–714CrossRefPubMedPubMedCentralGoogle Scholar
  138. Fernstrom JD, Fernstrom MH (2007) Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr 137:1539S–1547SCrossRefPubMedGoogle Scholar
  139. Fienberg AA, Hiroi N, Mermelstein PG et al (1998) DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281:838–842CrossRefPubMedGoogle Scholar
  140. Fleming AS, Suh EJ, Korsmit M, Rusak B (1994) Activation of Fos-like immunoreactivity in the medial preoptic area and limbic structures of maternal and social interactions in rats. Behav Neurosci 108:724CrossRefPubMedGoogle Scholar
  141. Flores-Barrera E, Thomases DR, Heng LJ et al (2014) Late adolescent expression of GluN2B transmission in the prefrontal cortex is input-specific and requires postsynaptic protein kinase A and D1 dopamine receptor signaling. Biol Psychiatry 75:508–516.  https://doi.org/10.1016/j.biopsych.2013.07.033 CrossRefPubMedGoogle Scholar
  142. Floresco SB, Maric TT (2007) Dopaminergic regulation of inhibitory and excitatory transmission in the basolateral amygdala–prefrontal cortical pathway. J Neurosci 27:2045–2057CrossRefPubMedGoogle Scholar
  143. Floresco SB, West AR, Ash B et al (2003) Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci 6:968CrossRefPubMedGoogle Scholar
  144. Foster DJ, Conn PJ (2017) Allosteric modulation of GPCRs: new insights and potential utility for treatment of schizophrenia and other CNS disorders. Neuron 94:431–446.  https://doi.org/10.1016/j.neuron.2017.03.016 CrossRefPubMedPubMedCentralGoogle Scholar
  145. Frankel JS, Schwartz TL (2017) Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol 7:29–41.  https://doi.org/10.1177/2045125316672136 CrossRefGoogle Scholar
  146. Frankle WG, Laruelle M (2002) Neuroreceptor imaging in psychiatric disorders. Ann Nucl Med 16:437CrossRefPubMedGoogle Scholar
  147. Freedman R (2003) Schizophrenia. N Engl J Med 349:1738–1749.  https://doi.org/10.1056/NEJMra035458 CrossRefPubMedGoogle Scholar
  148. Freyberg Z, Ferrando SJ, Javitch JA (2010) Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 167:388–396.  https://doi.org/10.1176/appi.ajp.2009.08121873 CrossRefPubMedGoogle Scholar
  149. Gainetdinov RR, Wetsel WC, Jones SR et al (1999) Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283:397–401CrossRefPubMedGoogle Scholar
  150. Gainetdinov RR, Bohn LM, Sotnikova TD et al (2003) Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron 38:291–303.  https://doi.org/10.1016/S0896-6273(03)00192-2 CrossRefPubMedGoogle Scholar
  151. Gandhi S, Wood NW (2005) Molecular pathogenesis of Parkinson’s disease. Hum Mol Genet 14:2749–2755CrossRefPubMedGoogle Scholar
  152. Gao Y, Peterson S, Masri B et al (2015) Cariprazine exerts antimanic properties and interferes with dopamine D2receptor β-arrestin interactions. Pharmacol Res Perspect 3:1–10.  https://doi.org/10.1002/prp2.73 CrossRefGoogle Scholar
  153. Gardner EL (2011) Addiction and brain reward and antireward pathways. Adv Psychosom Med 30:22–60CrossRefPubMedPubMedCentralGoogle Scholar
  154. Gardner B, Hall DA, Strange PG (1996) Pharmacological analysis of dopamine stimulation of [35S]-GTP gamma binding via human D2short and D2long dopamine receptors expressed in recombinant cells. Br J Pharmacol 118:1544–1550CrossRefPubMedPubMedCentralGoogle Scholar
  155. Gardner BR, Hall DA, Strange PG (1997) Agonist action at D2 (short) dopamine receptors determined in ligand binding and functional assays. J Neurochem 69:2589–2598CrossRefPubMedGoogle Scholar
  156. Garris PA, Ciolkowski EL, Pastore P, Wightman RM (1994) Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J Neurosci 14:6084–6093CrossRefPubMedGoogle Scholar
  157. Gasbarri A, Sulli A, Packard MG (1997) The dopaminergic mesencephalic projections to the hippocampal formation in the rat. Prog Neuro-Psychopharmacol Biol Psychiatry 21:1–22CrossRefGoogle Scholar
  158. Gerfen CR, Surmeier DJ (2011) Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 34:441–466CrossRefPubMedPubMedCentralGoogle Scholar
  159. Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752CrossRefPubMedPubMedCentralGoogle Scholar
  160. Gingrich JA, Caron MG (1993) Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci 16:299–321CrossRefPubMedGoogle Scholar
  161. Giordano AL, Johnson AE, Rosenblatt JS (1990) Haloperidol-induced disruption of retrieval behavior and reversal with apomorphine in lactating rats. Physiol Behav 48:211–214CrossRefPubMedGoogle Scholar
  162. Girault JA, Hemmings HCJ, Williams KR et al (1989) Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, by casein kinase II. J Biol Chem 264:21748–21759PubMedGoogle Scholar
  163. Giros B, Sokoloff P, Martres MP et al (1989) Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature 342:923–926.  https://doi.org/10.1038/342923a0 CrossRefGoogle Scholar
  164. Giros B, Martres MP, Pilon C et al (1991) Shorter variants of the D3dopamine receptor produced through various patterns of alternative splicing. Biochem Biophys Res Commun 176:1584–1592.  https://doi.org/10.1016/0006-291X(91)90469-N CrossRefPubMedGoogle Scholar
  165. Giros B, Jaber M, Jones SR et al (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606–612CrossRefPubMedGoogle Scholar
  166. Gizer IR, Ficks C, Waldman ID (2009) Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 126:51–90CrossRefPubMedGoogle Scholar
  167. Gold JM, Waltz JA, Matveeva TM et al (2012) Negative symptoms and the failure to represent the expected reward value of actions: behavioral and computational modeling evidence. Arch Gen Psychiatry 69:129–138CrossRefPubMedPubMedCentralGoogle Scholar
  168. Goldberg LI, Volkman PH, Kohli JD (1978) A comparison of the vascular dopamine receptor with other dopamine receptors. Annu Rev Pharmacol Toxicol 18:57–79CrossRefPubMedGoogle Scholar
  169. Gomez-Sintes R, Bortolozzi A, Artigas F, Lucas JJ (2014) Reduced striatal dopamine DA D2 receptor function in dominant-negative GSK-3 transgenic mice. Eur Neuropsychopharmacol 24:1524–1533.  https://doi.org/10.1016/j.euroneuro.2014.07.004 CrossRefPubMedGoogle Scholar
  170. Goto Y, Otani S, Grace AA (2007) The Yin and Yang of dopamine release: a new perspective. Neuropharmacology 53:583–587.  https://doi.org/10.1016/j.neuropharm.2007.07.007 CrossRefPubMedPubMedCentralGoogle Scholar
  171. Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41:1–24CrossRefPubMedGoogle Scholar
  172. Grace AA, Floresco SB, Goto Y, Lodge DJ (2007) Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci 30:220–227.  https://doi.org/10.1016/j.tins.2007.03.003 CrossRefPubMedGoogle Scholar
  173. Grattan DR, Averill RLW (1995) Absence of short-loop autoregulation of prolactin during late pregnancy in the rat. Brain Res Bull 36:413–416.  https://doi.org/10.1016/0361-9230(94)00216-N CrossRefPubMedGoogle Scholar
  174. Graybiel AM (1997) The basal ganglia and cognitive pattern generators. Schizophr Bull 23:459CrossRefPubMedGoogle Scholar
  175. Graybiel AM (2000) The basal ganglia. Curr Biol 10:R509–R511CrossRefPubMedGoogle Scholar
  176. Greengard P (2001) The neurobiology of slow synaptic transmission. Science 294:1024–1030.  https://doi.org/10.1126/science.294.5544.1024 CrossRefPubMedGoogle Scholar
  177. Gregerson KA, Chuknyiska R, Golesorkhi N (1994) Stimulation of prolactin release by dopamine withdrawal: role of calcium influx. Am J Physiol 267:E789–E794PubMedGoogle Scholar
  178. Gresch PJ, Sved AF, Zigmond MJ, Finlay JM (1995) Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J Neurochem 65:111–116CrossRefPubMedGoogle Scholar
  179. Grossman GH, Mistlberger RE, Antle MC et al (2000) Sleep deprivation stimulates serotonin release in the suprachiasmatic nucleus. Neuroreport 11:1929–1932CrossRefPubMedGoogle Scholar
  180. Gu H (2013) Stem cell-derived neurons for the treatment of neurodegenerative diseases. Clin Pharmacol Biopharm 2:1000111/1–1000111/4.  https://doi.org/10.4172/2167-065X.1000111 CrossRefGoogle Scholar
  181. Gudelsky GA (1981) Tuberoinfundibular dopamine neurons and the regulation of prolactin secretion. Psychoneuroendocrinology 6:3–16CrossRefPubMedGoogle Scholar
  182. Gudelsky G, Porter J (1980) Release of dopamine from tuberoinfundibular neurons into pituitary stalk blood after prolactin or haloperidol administration. Endocrinology 106:526–529CrossRefPubMedGoogle Scholar
  183. Guillot TS, Miller GW (2009) Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol Neurobiol 39:149–170.  https://doi.org/10.1007/s12035-009-8059-y CrossRefPubMedGoogle Scholar
  184. Gurevich VV, Gurevich EV (2006) The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol Ther 110:465–502.  https://doi.org/10.1016/j.pharmthera.2005.09.008 CrossRefPubMedPubMedCentralGoogle Scholar
  185. Gurevich VV, Gurevich EV (2014) Overview of different mechanisms of arrestin-mediated signaling. Curr Protoc Pharmacol 67:1–9.  https://doi.org/10.1002/0471141755.ph0210s67 CrossRefGoogle Scholar
  186. Gurevich EV, Benovic JL, Gurevich VV (2002) Arrestin2 and arrestin3 are differentially expressed in the rat brain during postnatal development. Neuroscience 109:421–436.  https://doi.org/10.1016/S0306-4522(01)00511-5 CrossRefPubMedGoogle Scholar
  187. Gurevich EV, Gainetdinov RR, Gurevich VV (2016) G protein-coupled receptor kinases as regulators of dopamine receptor functions. Pharmacol Res 111:1–16.  https://doi.org/10.1016/j.phrs.2016.05.010 CrossRefPubMedPubMedCentralGoogle Scholar
  188. Ha AD, Fung VSC (2012) Huntington’s disease. Curr Opin Neurol 25:491–498CrossRefPubMedGoogle Scholar
  189. Ha AD, Jankovic J (2011) Exploring the correlates of intermediate CAG repeats in Huntington disease. Postgrad Med 123:116–121CrossRefPubMedGoogle Scholar
  190. Haber SN (2003) The primate basal ganglia: parallel and integrative networks. J Chem Neuroanat 26:317–330CrossRefPubMedGoogle Scholar
  191. Halpain S, Girault J-A, Greengard P (1990) Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices. Nature 343:369–372.  https://doi.org/10.1038/343369a0 CrossRefPubMedGoogle Scholar
  192. Hampson EC, Vaney DI, Weiler R (1992) Dopaminergic modulation of gap junction permeability between amacrine cells in mammalian retina. J Neurosci 12:4911–4922CrossRefPubMedGoogle Scholar
  193. Hansen S (1994) Maternal behavior of female rats with 6-OHDA lesions in the ventral striatum: characterization of the pup retrieval deficit. Physiol Behav 55:615–620CrossRefPubMedGoogle Scholar
  194. Hansen S, Harthon C, Wallin E et al (1991) The effects of 6-OHDA-induced dopamine depletions in the ventral or dorsal striatum on maternal and sexual behavior in the female rat. Pharmacol Biochem Behav 39:71–77CrossRefPubMedGoogle Scholar
  195. Harrington KA, Augood SJ, Kingsbury AE et al (1996) Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson’s disease. Mol brain Res 36:157–162CrossRefPubMedGoogle Scholar
  196. Hasue RH, Shammah-Lagnado SJ (2002) Origin of the dopaminergic innervation of the central extended amygdala and accumbens shell: a combined retrograde tracing and immunohistochemical study in the rat. J Comp Neurol 454:15–33CrossRefPubMedGoogle Scholar
  197. Hauser DN, Hastings TG (2013) Mitochondrial dysfunction and oxidative stress in Parkinson’s disease and monogenic parkinsonism. Neurobiol Dis 51:35–42.  https://doi.org/10.1016/j.nbd.2012.10.011 CrossRefGoogle Scholar
  198. Hemmings HC, Greengard P, Tung HYL, Cohen P (1984a) DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 310:503–505.  https://doi.org/10.1038/310503a0 CrossRefPubMedGoogle Scholar
  199. Hemmings HC, Nairn AC, Greengard P (1984b) DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated neuronal phosphoprotein. II. Comparison of the kinetics of phosphorylation of DARPP-32 and phosphatase inhibitor 1. J Biol Chem 259:14491–14497PubMedGoogle Scholar
  200. Henry DJ, Hu X-T, White FJ (1998) Adaptations in the mesoaccumbens dopamine system resulting from repeated administration of dopamine D1 and D2 receptor-selective agonists: relevance to cocaine sensitization. Psychopharmacology 140:233–242CrossRefPubMedGoogle Scholar
  201. Hernandez DG, Reed X, Singleton AB (2016) Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. J Neurochem 139 Suppl:59–74.  https://doi.org/10.1111/jnc.13593 CrossRefPubMedPubMedCentralGoogle Scholar
  202. Hernandez-Lopez S, Tkatch T, Perez-Garci E et al (2000) D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2 + currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. J Neurosci 20:8987–8995 doi: 20/24/8987 [pii]CrossRefPubMedGoogle Scholar
  203. Herrera-Soto A, Diaz-Veliz G, Mora S et al (2017) On the role of DT-diaphorase inhibition in aminochrome-induced neurotoxicity in vivo. Neurotox Res 32:134–140CrossRefPubMedGoogle Scholar
  204. Heximer SP, Blumer KJ (2007) RGS proteins: swiss army knives in seven-transmembrane domain receptor signaling networks. Sci STKE 2007:.  https://doi.org/10.1126/stke.3702007pe2
  205. Hikosaka O, Nakamura K, Sakai K, Nakahara H (2002) Central mechanisms of motor skill learning. Curr Opin Neurobiol 12:217–222CrossRefPubMedGoogle Scholar
  206. Hnasko TS, Edwards RH (2012) Neurotransmitter corelease: mechanism and physiological role. Annu Rev Physiol 74:225–243CrossRefPubMedGoogle Scholar
  207. Hohman LB (1922) Post-encephalitic behavior disorders in children. Johns Hopkins Hospt Bull 33:372–375Google Scholar
  208. Hollinger S, Hepler JR (2002) Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev 54:527–559.  https://doi.org/10.1124/pr.54.3.527 CrossRefPubMedGoogle Scholar
  209. Holstege JC, Van Dijken H, Buijs RM et al (1996) Distribution of dopamine immunoreactivity in the rat, cat, and monkey spinal cord. J Comp Neurol 376:631–652CrossRefPubMedGoogle Scholar
  210. Horvitz JC (2000) Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. Neuroscience 96:651–656CrossRefPubMedGoogle Scholar
  211. Howes OD, McCutcheon R, Owen MJ, Murray RM (2017) The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry 81:9–20.  https://doi.org/10.1016/j.biopsych.2016.07.014 CrossRefPubMedGoogle Scholar
  212. Hu X-T, Dong Y, Zhang X-F, White FJ (2005) Dopamine D2 receptor-activated Ca2 + signaling modulates voltage-sensitive sodium currents in rat nucleus accumbens neurons. J Neurophysiol 93:1406–1417.  https://doi.org/10.1152/jn.00771.2004 CrossRefPubMedGoogle Scholar
  213. Hu W, MacDonald ML, Elswick DE, Sweet RA (2015) The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann N Y Acad Sci 1338:38–57CrossRefPubMedGoogle Scholar
  214. Huenchuguala S, Muñoz P, Graumann R et al (2016) DT-diaphorase protects astrocytes from aminochrome-induced toxicity. Neurotoxicology 55:10–12CrossRefPubMedGoogle Scholar
  215. Huenchuguala S, Muñoz P, Segura-Aguilar J (2017) The importance of mitophagy in maintaining mitochondrial function in U373MG Cells. Bafilomycin A1 restores aminochrome-induced mitochondrial damage. ACS Chem Neurosci 8:2247–2253CrossRefPubMedGoogle Scholar
  216. Ikemoto S (2007) Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens–olfactory tubercle complex. Brain Res Rev 56:27–78CrossRefPubMedPubMedCentralGoogle Scholar
  217. Ikemoto S, Panksepp J (1999) The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res Rev 31:6–41CrossRefPubMedGoogle Scholar
  218. Iversen LL (1971) Role of transmitter uptake mechanisms in synaptic neurotransmission. Br J Pharmacol 41:571–591CrossRefPubMedPubMedCentralGoogle Scholar
  219. Iversen SD, Iversen LL (2007) Dopamine: 50 years in perspective. Trends Neurosci 30:188–193CrossRefPubMedGoogle Scholar
  220. Jakel RJ, Maragos WF (2000) Neuronal cell death in Huntington’s disease: a potential role for dopamine. Trends Neurosci 23:239–245CrossRefPubMedGoogle Scholar
  221. Jones CK, Byun N, Bubser M (2012) Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 37:16CrossRefPubMedGoogle Scholar
  222. Jose PA, Yu PY, Yamaguchi I et al (1995) Dopamine D1 receptor regulation of phospholipase C. Hypertens Res 18(Suppl 1):S39–S42CrossRefPubMedGoogle Scholar
  223. Jose PA, Eisner GM, Felder RA (2002) Role of dopamine receptors in the kidney in the regulation of blood pressure. Curr Opin Nephrol Hypertens 11:87–92.  https://doi.org/10.1097/00041552-200201000-00013 CrossRefPubMedGoogle Scholar
  224. Joyce EM, Roiser JP (2007) Cognitive heterogeneity in schizophrenia. Curr Opin Psychiatry 20:268CrossRefPubMedPubMedCentralGoogle Scholar
  225. Kahn RS, Sommer IE, Murray RM et al (2015) Schizophrenia. Nat Rev Dis Prim 1:15067.  https://doi.org/10.1038/nrdp.2015.67 CrossRefPubMedGoogle Scholar
  226. Kaidanovich-Beilin O, Woodgett JR (2011) GSK-3: functional insights from cell biology and animal models. Front Mol Neurosci 4:40.  https://doi.org/10.3389/fnmol.2011.00040 CrossRefPubMedPubMedCentralGoogle Scholar
  227. Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386:896–912.  https://doi.org/10.1016/S0140-6736(14)61393-3 CrossRefGoogle Scholar
  228. Kambeitz J, Abi-Dargham A, Kapur S, Howes OD (2014) Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. Br J Psychiatry 204:420–429CrossRefPubMedGoogle Scholar
  229. Kandel E, Jessell TM, Schwartz JH et al (2013) Principles of neural science. McGraw-Hill Education, New YorkGoogle Scholar
  230. Kanner BI, Schuldiner S (1987) Mechanism of transport and storage of neurotransmitter. Crit Rev Biochem 22:1–38CrossRefGoogle Scholar
  231. Kebabian JW (1978) Multiple classes of dopamine receptors in mammalian central nervous system: the involvement of dopamine-sensitive adenylyl cyclase. Life Sci 23:479–483.  https://doi.org/10.1016/0024-3205(78)90157-1 CrossRefPubMedGoogle Scholar
  232. Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277:93–96.  https://doi.org/10.1038/277093a0 CrossRefPubMedGoogle Scholar
  233. Kebabian JW, Greengard P (1971) Dopamine-sensitive adenyl cyclase: possible role in synaptic transmission. Science 174:1346–1349.  https://doi.org/10.1126/science.174.4016.1346 CrossRefPubMedGoogle Scholar
  234. Kebabian JW, Petzold GL, Greengard P (1972) Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the “dopamine receptor”. Proc Natl Acad Sci USA 69:2145–2149.  https://doi.org/10.1073/PNAS.69.8.2145 CrossRefPubMedGoogle Scholar
  235. Kelley AE, Berridge KC (2002) The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 22:3306–3311CrossRefPubMedGoogle Scholar
  236. Kenny PJ (2011) Common cellular and molecular mechanisms in obesity and drug addiction. Nat Rev Neurosci 12:638CrossRefPubMedGoogle Scholar
  237. Kim EK, Choi E-J (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta (BBA) 1802:396–405CrossRefGoogle Scholar
  238. Kim SD, Fung VSC (2014) An update on Huntington’s disease: from the gene to the clinic. Curr Opin Neurol 27:477–483CrossRefPubMedGoogle Scholar
  239. Kim KM, Valenzano KJ, Robinson SR et al (2001) Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins. J Biol Chem 276:37409–37414.  https://doi.org/10.1074/jbc.M106728200 CrossRefPubMedGoogle Scholar
  240. Kim SJ, Kim MY, Lee EJ et al (2004) Distinct regulation of internalization and mitogen-activated protein kinase activation by two isoforms of the dopamine D2 receptor. Mol Endocrinol 18:640–652.  https://doi.org/10.1210/me.2003-0066 CrossRefPubMedGoogle Scholar
  241. King MM, Huang CY, Chock PB et al (1984) Mammalian brain phosphoproteins as substrates for calcineurin. J Biol Chem 259:8080–8083PubMedGoogle Scholar
  242. Kiss B, Horvath A, Nemethy Z et al (2010) Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 333:328–340.  https://doi.org/10.1124/jpet.109.160432 CrossRefPubMedGoogle Scholar
  243. Komolov KE, Benovic JL (2018) G protein-coupled receptor kinases: past, present and future. Cell Signal 41:17–24.  https://doi.org/10.1016/j.cellsig.2017.07.004 CrossRefPubMedGoogle Scholar
  244. Koob GF, Le Moal M (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278:52–58CrossRefPubMedGoogle Scholar
  245. Koob GF, Sanna PP, Bloom FE (1998) Neuroscience of addiction. Neuron 21:467–476CrossRefPubMedGoogle Scholar
  246. Kortekaas R, Leenders KL, van Oostrom JCH et al (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57:176–179CrossRefPubMedGoogle Scholar
  247. Kovoor A, Seyffarth P, Ebert J et al (2005) D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. J Neurosci 25:2157–2165.  https://doi.org/10.1523/JNEUROSCI.2840-04.2005 CrossRefPubMedGoogle Scholar
  248. Kravitz AV, Freeze BS, Parker PRL et al (2010) Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 466:622CrossRefPubMedPubMedCentralGoogle Scholar
  249. Krüger THC, Hartmann U, Schedlowski M (2005) Prolactinergic and dopaminergic mechanisms underlying sexual arousal and orgasm in humans. World J Urol 23:130–138CrossRefPubMedGoogle Scholar
  250. Kuzhikandathil EV, Yu W, Oxford GS (1998) Human dopamine D3 and D2L receptors couple to inward rectifier potassium channels in mammalian cell lines. Mol Cell Neurosci 12:390–402.  https://doi.org/10.1006/mcne.1998.0722 CrossRefPubMedGoogle Scholar
  251. Lange KW, Reichl S, Lange KM et al (2010) The history of attention deficit hyperactivity disorder. ADHD Atten Deficit Hyperact Disord 2:241–255CrossRefGoogle Scholar
  252. Laporte SA, Miller WE, Kim K-M, Caron MG (2002) Beta-Arrestin/AP-2 interaction in G protein-coupled receptor internalization: identification of a beta-arrestin binging site in beta 2-adaptin. J Biol Chem 277:9247–9254.  https://doi.org/10.1074/jbc.M108490200 CrossRefPubMedGoogle Scholar
  253. Ledonne A, Berretta N, Davoli A et al (2011) Electrophysiological effects of trace amines on mesencephalic dopaminergic neurons. Front Syst Neurosci 5:56CrossRefPubMedPubMedCentralGoogle Scholar
  254. Lee M, O’Regan S, Moreau JL et al (2000) Regulation of the PcI7-Pho85 cyclin-cdk complex by Pho81. Mol Microbiol 38:411–422.  https://doi.org/10.1046/j.1365-2958.2000.02140.x CrossRefPubMedGoogle Scholar
  255. Lee SP, So CH, Rashid AJ et al (2004) Dopamine D1 and D2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem 279:35671–35678.  https://doi.org/10.1074/jbc.M401923200 CrossRefPubMedGoogle Scholar
  256. Lee S, Hjerling-Leffler J, Zagha E et al (2010) The largest group of superficial neocortical GABAergic interneurons expresses ionotropic serotonin receptors. J Neurosci 30:16796–16808CrossRefPubMedPubMedCentralGoogle Scholar
  257. Lee S-M, Yang Y, Mailman RB (2014) Dopamine D1 receptor signaling: does GαQ-phospholipase C actually play a role? J Pharmacol Exp Ther 351:9–17.  https://doi.org/10.1124/jpet.114.214411 CrossRefPubMedPubMedCentralGoogle Scholar
  258. Leggio GM, Bucolo C, Platania CBM et al (2016) Current drug treatments targeting dopamine D3 receptor. Pharmacol Ther 165:164–177.  https://doi.org/10.1016/j.pharmthera.2016.06.007 CrossRefPubMedGoogle Scholar
  259. Levesque D, Diaz J, Pilon C et al (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H] hydroxy-N, N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci 89:8155–8159CrossRefPubMedGoogle Scholar
  260. Li C, Chen P, Smith MS (1999) Neuropeptide Y and tuberoinfundibular dopamine activities are altered during lactation: role of prolactin. Endocrinology 140:118–123CrossRefPubMedGoogle Scholar
  261. Li D, Sham PC, Owen MJ, He L (2006) Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum Mol Genet 15:2276–2284CrossRefPubMedGoogle Scholar
  262. Li Y-C, Xi D, Roman J et al (2009) Activation of glycogen synthase kinase-3 is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex. J Neurosci 29:15551–15563.  https://doi.org/10.1523/JNEUROSCI.3336-09.2009 CrossRefPubMedPubMedCentralGoogle Scholar
  263. Li L, Homan KT, Vishnivetskiy SA et al (2015) G protein-coupled receptor kinases of the GRK4 protein subfamily phosphorylate inactive G protein-coupled receptors (GPCRs). J Biol Chem 290:10775–10790.  https://doi.org/10.1074/jbc.M115.644773 CrossRefPubMedPubMedCentralGoogle Scholar
  264. Liang C-L, Nelson O, Yazdani U et al (2004) Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons. J Comp Neurol 473:97–106CrossRefPubMedGoogle Scholar
  265. Lieberman JA, Kane JM, Alvir J (1987) Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 91:415–433CrossRefPubMedGoogle Scholar
  266. Lindemann L, Meyer CA, Jeanneau K et al (2008) Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther 324:948–956CrossRefPubMedGoogle Scholar
  267. Lindvall OL, Björklund AB, Skagerberg G (1983) Dopamine-containing neurons in the spinal cord: anatomy and some functional aspects. Ann Neurol Off J Am Neurol Assoc Child Neurol Soc 14:255–260Google Scholar
  268. Liu F, Wan Q, Pristupa ZB et al (2000) Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors. Nature 403:274–280.  https://doi.org/10.1038/35002014 CrossRefPubMedGoogle Scholar
  269. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627–644.  https://doi.org/10.1038/nrd2926 CrossRefPubMedPubMedCentralGoogle Scholar
  270. Liu C, Kershberg L, Wang J et al (2018) Dopamine secretion is mediated by sparse active zone-like release sites. Cell 172:706–718.e15.  https://doi.org/10.1016/j.cell.2018.01.008 CrossRefPubMedPubMedCentralGoogle Scholar
  271. Loewi O (1921) Über humorale übertragbarkeit der Herznervenwirkung. Pflüger’s Arch für die gesamte Physiol des Menschen der Tiere 189:239–242CrossRefGoogle Scholar
  272. Lohse MJ, Benovic JL, Codina J et al (1990) beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Science 248:1547–1550.  https://doi.org/10.1126/science.2163110 CrossRefPubMedGoogle Scholar
  273. Loughlin SE, Fallon JH (1983) Dopaminergic and non-dopaminergic projections to amygdala from substantia nigra and ventral tegmental area. Brain Res 262:334–338CrossRefPubMedGoogle Scholar
  274. Lozano J, Munoz P, Nore BF et al (2010) Stable expression of short interfering RNA for DT-diaphorase induces neurotoxicity. Chem Res Toxicol 23:1492–1496CrossRefPubMedGoogle Scholar
  275. Luciana M, Collins PF, Depue RA (1998) Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Cereb Cortex 8:218–226CrossRefPubMedGoogle Scholar
  276. Luttrell LM, Lefkowitz RJ (2002) The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 115:455–465.  https://doi.org/10.1074/jbc.274.3.1185 CrossRefPubMedGoogle Scholar
  277. Lynch WJ, Peterson AB, Sanchez V et al (2013) Exercise as a novel treatment for drug addiction: a neurobiological and stage-dependent hypothesis. Neurosci Biobehav Rev 37:1622–1644CrossRefPubMedPubMedCentralGoogle Scholar
  278. Ma J, Long LH, Hu ZL et al (2015) Activation of D1-like receptor-dependent phosphatidylinositol signal pathway by SKF83959 inhibits voltage-gated sodium channels in cultured striatal neurons. Brain Res 1615:71–79.  https://doi.org/10.1016/j.brainres.2015.04.030 CrossRefPubMedGoogle Scholar
  279. MacDermott AB, Role LW, Siegelbaum SA (1999) Presynaptic ionotropic receptors and the control of transmitter release. Annu Rev Neurosci 22:443–485CrossRefPubMedGoogle Scholar
  280. MacDonald ME, Ambrose CM, Duyao MP et al (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983CrossRefGoogle Scholar
  281. Madras BK, Miller GM, Fischman AJ (2005) The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1397–1409CrossRefGoogle Scholar
  282. Maeda K, Sugino H, Akazawa H et al (2014) Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 350:589–604.  https://doi.org/10.1124/jpet.114.213793 CrossRefGoogle Scholar
  283. Magnusson JE, Fisher K (2000) The involvement of dopamine in nociception: the role of D1 and D2 receptors in the dorsolateral striatum. Brain Res 855:260–266CrossRefPubMedGoogle Scholar
  284. Maia TV, Frank MJ (2017) An integrative perspective on the role of dopamine in schizophrenia. Biol Psychiatry 81:52–66CrossRefPubMedGoogle Scholar
  285. Manger PR, Fuxe K, Ridgway SH, Siegel JM (2004) The distribution and morphological characteristics of catecholaminergic cells in the diencephalon and midbrain of the bottlenose dolphin (Tursiops truncatus). Brain Behav Evol 64:42–60CrossRefPubMedGoogle Scholar
  286. Martelli AM, Chiarini F, Evangelisti C et al (2010) The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. Histol Histopathol 25:669–680PubMedGoogle Scholar
  287. Martinez G, Weiner RI, Martinez G (1992) Dissociation of dopamine from its receptor as a signal in the pleiotropic hypothalamic regulation of prolactin secretion. Endocr Rev 13:241–245.  https://doi.org/10.1210/edrv-13-2-241 CrossRefGoogle Scholar
  288. Martini M, De Santis MC, Braccini L et al (2014) PI3K/AKT signaling pathway and cancer: an updated review. Ann Med 46:372–383.  https://doi.org/10.3109/07853890.2014.912836 CrossRefPubMedGoogle Scholar
  289. Matthews M, Nigg JT, Fair DA (2014) Attention deficit hyperactivity disorder. Curr Top Behav Neurosci 16:235–266.  https://doi.org/10.1007/7854_2013_249 CrossRefPubMedPubMedCentralGoogle Scholar
  290. Meyer N, MacCabe JH (2016) Schizophrenia. Medicine (Baltimore) 44:649–653.  https://doi.org/10.1016/j.mpmed.2016.08.003 CrossRefGoogle Scholar
  291. Michael-Titus A, Bousselmame R, Costentin J (1990) Stimulation of dopamine D2 receptors induces an analgesia involving an opiodergic but non enkephalinergic link. Eur J Pharmacol 187:201–207CrossRefPubMedGoogle Scholar
  292. Miller GW, Gainetdinov RR, Levey AI, Caron MG (1999) Dopamine transporters and neuronal injury. Trends Pharmacol Sci 20:424–429CrossRefPubMedGoogle Scholar
  293. Miller JS, Barr JL, Harper LJ et al (2014) The GSK3 signaling pathway is activated by cocaine and is critical for cocaine conditioned reward in mice. PLoS ONE 9:.  https://doi.org/10.1371/journal.pone.0088026
  294. Milligan G (2009) G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br J Pharmacol 158:5–14.  https://doi.org/10.1111/j.1476-5381.2009.00169.x CrossRefPubMedPubMedCentralGoogle Scholar
  295. Missale C, Nash SR, Robinson SW et al (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189–225CrossRefPubMedGoogle Scholar
  296. Missale C, Fiorentini C, Collo G, Spano P (2010) The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes. J Recept Signal Transduct 30:347–354.  https://doi.org/10.3109/10799893.2010.506192 CrossRefGoogle Scholar
  297. Mitchell HA, Weinshenker D (2010) Good night and good luck: norepinephrine in sleep pharmacology. Biochem Pharmacol 79:801–809CrossRefPubMedGoogle Scholar
  298. Mogenson GJ, Nielsen M (1984) Neuropharmacological evidence to suggest that the nucleus accumbens and subpallidal region contribute to exploratory locomotion. Behav Neural Biol 42:52–60CrossRefPubMedGoogle Scholar
  299. Mogenson GJ, Wu M, Jones DL (1980) Locomotor activity elicited by injections of picrotoxin into the ventral tegmental area is attenuated by injections of GABA into the globus pallidus. Brain Res 191:569–571CrossRefPubMedGoogle Scholar
  300. Moore KE (1987) Interactions between prolactin and dopaminergic neurons. Biol Reprod 36:47–58.  https://doi.org/10.1095/biolreprod36.1.47 CrossRefPubMedGoogle Scholar
  301. Morelli M, Carboni E, Cozzolino A et al (1992) Combined microdialysis and fos immunohistochemistry for the estimation of dopamine neurotransmission in the rat caudate-putamen. J Neurochem 59:1158–1160CrossRefPubMedGoogle Scholar
  302. Morimoto S, Takao M, Hatsuta H et al (2017) Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer’s disease: An autopsy-confirmed study. PLoS ONE 12:e0171524CrossRefPubMedPubMedCentralGoogle Scholar
  303. Morón JA, Brockington A, Wise RA et al (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 22:389–395CrossRefPubMedGoogle Scholar
  304. Mougeot JLC, Hirsch MA, Stevens CB, Mougeot FKB (2016) Oral biomarkers in exercise-induced neuroplasticity in Parkinson’s disease. Oral Dis 22:745–753.  https://doi.org/10.1111/odi.12463 CrossRefPubMedPubMedCentralGoogle Scholar
  305. Murphy JA, Stein IS, Lau CG et al (2014) Phosphorylation of Ser1166 on GluN2B by PKA is critical to synaptic NMDA receptor function and Ca 2+ signaling in spines. J Neurosci 34:869–879.  https://doi.org/10.1523/JNEUROSCI.4538-13.2014 CrossRefPubMedPubMedCentralGoogle Scholar
  306. Mushegian A, Gurevich VV, Gurevich EV (2012) The origin and evolution of G protein-coupled receptor kinases. PLoS One 7:.  https://doi.org/10.1371/journal.pone.0033806
  307. Myers RH, Sax DS, Schoenfeld M et al (1985) Late onset of Huntington’s disease. J Neurol Neurosurg Psychiatry 48:530–534CrossRefPubMedPubMedCentralGoogle Scholar
  308. Nagatsu T, Levitt M, Udenfriend S (1964) Tyrosine hydroxylase the initial step in norepinephrine biosynthesis. J Biol Chem 239:2910–2917PubMedGoogle Scholar
  309. Nakagawa M, Kuri M, Kambara N et al (2008) Dopamine D2 receptor Taq IA polymorphism is associated with postoperative nausea and vomiting. J Anesth 22:397–403CrossRefPubMedGoogle Scholar
  310. Newman-Tancredi A, Nicolas J-P, Audinot V et al (1998) Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 358:197–206CrossRefPubMedGoogle Scholar
  311. Nigg JT (2013) Attention-deficit/hyperactivity disorder and adverse health outcomes. Clin Psychol Rev 33:215–228CrossRefPubMedGoogle Scholar
  312. Nikolaus S, Antke C, Müller H-W (2009) In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia. Behav Brain Res 204:1–31CrossRefPubMedGoogle Scholar
  313. Nishi A, Snyder GL, Greengard P (1997) Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci 17:8147–8155CrossRefPubMedGoogle Scholar
  314. Nishi A, Matamales M, Musante V et al (2017) Glutamate counteracts dopamine/pka signaling via dephosphorylation of DARPP-32 Ser-97 and alteration of its cytonuclear distribution. J Biol Chem 292:1462–1476.  https://doi.org/10.1074/jbc.M116.752402 CrossRefPubMedGoogle Scholar
  315. Noaín D, Avale ME, Wedemeyer C et al (2006) Identification of brain neurons expressing the dopamine D4 receptor gene using BAC transgenic mice. Eur J Neurosci 24:2429–2438CrossRefPubMedGoogle Scholar
  316. Numan M (2007) Motivational systems and the neural circuitry of maternal behavior in the rat. Dev Psychobiol 49:165–171.  https://doi.org/10.1002/dev CrossRefGoogle Scholar
  317. Numan M, Sheehan TP (1997) Neuroanatomical circuitry for mammalian maternal behavior. Ann N Y Acad Sci 807:101–125CrossRefPubMedGoogle Scholar
  318. Numan M, Smith HG (1984) Maternal behavior in rats: evidence for the involvement of preoptic projections to the ventral tegmental area. Behav Neurosci 98:712–712.  https://doi.org/10.1037/0735-7044.98.4.712 CrossRefPubMedGoogle Scholar
  319. Numan M, Numan MJ, Pliakou N et al (2005) The effects of D1 or D2 dopamine receptor antagonism in the medial preoptic area, ventral pallidum, or nucleus accumbens on the maternal retrieval response and other aspects of maternal behavior in rats. Behav Neurosci 119:1588–1604.  https://doi.org/10.1037/0735-7044.119.6.1588 CrossRefPubMedGoogle Scholar
  320. Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PRA (2015) The dopamine theory of addiction: 40 years of highs and lows. Nat Rev Neurosci 16:305CrossRefPubMedGoogle Scholar
  321. O’Brien WT, Huang J, Buccafusca R et al (2011) Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice. J Clin Invest 121:3756–3762.  https://doi.org/10.1172/JCI45194 CrossRefPubMedPubMedCentralGoogle Scholar
  322. O’Donnell P (2013) Of mice and men: what physiological correlates of cognitive deficits in a mouse model of schizophrenia tell us about psychiatric disease. Neuron 80:265–266CrossRefPubMedGoogle Scholar
  323. Obeso Jose A, Marin C, Rodriguez-Oroz C et al (2009) The basal ganglia in Parkinson’s disease: Current concepts and unexplained observations. Ann Neurol 64:S30–S46.  https://doi.org/10.1002/ana.21481 CrossRefGoogle Scholar
  324. Otmakhova N, Duzel E, Deutch AY, Lisman J (2013) The hippocampal-VTA loop: the role of novelty and motivation in controlling the entry of information into long-term memory. In: Baldassarre G, Mirolli M (eds) Intrinsically motivated learning in natural and artificial systems. Springer, Berlin, Heidelberg, pp 235–254CrossRefGoogle Scholar
  325. Owen MJ, Sawa A, Mortensen PB (2016) Schizophrenia Lancet 388:86–97.  https://doi.org/10.1016/S0140-6736(15)01121-6 CrossRefPubMedPubMedCentralGoogle Scholar
  326. Pan WHT, Yang S-Y, Lin S-K (2004) Neurochemical interaction between dopaminergic and noradrenergic neurons in the medial prefrontal cortex. Synapse 53:44–52CrossRefPubMedGoogle Scholar
  327. Pan B, Chen J, Lian J et al (2015) Unique effects of acute aripiprazole treatment on the dopamine D2 receptor downstream cAMP-PKA and Akt-GSK3β signalling pathways in rats. PLoS ONE 10:.  https://doi.org/10.1371/journal.pone.0132722
  328. Paoletti P, Vila I, Rifé M et al (2008) Dopaminergic and glutamatergic signaling crosstalk in Huntington’s disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. J Neurosci 28:10090–10101CrossRefPubMedPubMedCentralGoogle Scholar
  329. Parada M, King S, Li M, Fleming AS (2008) The roles of accumbal dopamine D1 and D2 receptors in maternal memory in rats. Behav Neurosci 122:368–376.  https://doi.org/10.1037/0735-7044.122.2.368 CrossRefPubMedGoogle Scholar
  330. Park SM, Chen M, Schmerberg CM et al (2016) Effects of β-arrestin-biased dopamine D2 receptor ligands on schizophrenia-like behavior in hypoglutamatergic mice. Neuropsychopharmacology 41:704–715.  https://doi.org/10.1038/npp.2015.196 CrossRefPubMedGoogle Scholar
  331. Parkinson JA, Olmstead MC, Burns LH et al (1999) Dissociation in effects of lesions of the nucleus accumbens core and shell on appetitive pavlovian approach behavior and the potentiation of conditioned reinforcement and locomotor activity byd-amphetamine. J Neurosci 19:2401–2411CrossRefPubMedGoogle Scholar
  332. Pascoli V, Besnard A, Herv D et al (2011) Cyclic adenosine monophosphateindependent tyrosine phosphorylation of NR2B mediates cocaine-induced extracellular signal-regulated kinase activation. Biol Psychiatry 69:218–227.  https://doi.org/10.1016/j.biopsych.2010.08.031 CrossRefPubMedGoogle Scholar
  333. Paul S, Nairn AC, Wang P, Lombroso PJ (2003) NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling. Nat Neurosci 6:34–42.  https://doi.org/10.1038/nn989 CrossRefPubMedGoogle Scholar
  334. Paus T (2001) Primate anterior cingulate cortex: where motor control, drive and cognition interface. Nat Rev Neurosci 2:417CrossRefPubMedGoogle Scholar
  335. Pedersen CA, Caldwell JD, Walker C et al (1994) Oxytocin activates the postpartum onset of rat maternal behavior in the ventral tegmental and medial preoptic areas. Behav Neurosci 108:1163CrossRefPubMedGoogle Scholar
  336. Peineau S, Taghibiglou C, Bradley C et al (2007) LTP Inhibits LTD in the Hippocampus via Regulation of GSK3β. Neuron 53:703–717.  https://doi.org/10.1016/j.neuron.2007.01.029 CrossRefPubMedGoogle Scholar
  337. Perez-Costas E, Melendez-Ferro M, Roberts RC (2010) Basal ganglia pathology in schizophrenia: dopamine connections and anomalies. J Neurochem 113:287–302CrossRefPubMedPubMedCentralGoogle Scholar
  338. Perreault ML, Hasbi A, O’dowd BF, George SR (2014) Heteromeric dopamine receptor signaling complexes: Emerging neurobiology and disease relevance. Neuropsychopharmacology 39:156–168.  https://doi.org/10.1038/npp.2013.148 CrossRefPubMedGoogle Scholar
  339. Peterson SM, Pack TF, Wilkins AD et al (2015) Elucidation of G-protein and β-arrestin functional selectivity at the dopamine D2 receptor. Proc Natl Acad Sci 112:7097–7102.  https://doi.org/10.1073/pnas.1502742112 CrossRefPubMedGoogle Scholar
  340. Peyron C, Luppi P-H, Kitahama K et al (1995) Origin of the dopaminergic innervation of the rat dorsal raphe nucleus. Neuroreport 6:2527–2531CrossRefPubMedGoogle Scholar
  341. Pierce KL, Premont RT, Lefkowitz RJ (2002) Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3:639–650.  https://doi.org/10.1038/nrm908 CrossRefGoogle Scholar
  342. Pijnenburg AJ, Van Rossum JM (1973) Stimulation of locomotor activity following injection of dopamine into the nucleus accumbens. J Pharmacy Pharmacol 25:1003–1005CrossRefGoogle Scholar
  343. Pitcher JA, Freedman NJ, Lefkowitz RJ (1998) G protein-coupled receptor kinases. Annu Rev Biochem 67:653–692.  https://doi.org/10.1146/annurev.biochem.67.1.653 CrossRefPubMedGoogle Scholar
  344. Poewe W (2008) Non-motor symptoms in Parkinson’s disease. Eur J Neurol 15:14–20CrossRefGoogle Scholar
  345. Polanczyk G, De Lima MS, Horta BL et al (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J PsychiatryGoogle Scholar
  346. Popat RA, Van Den Eeden SK, Tanner CM et al (2005) Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 65:383–390CrossRefPubMedGoogle Scholar
  347. Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601CrossRefPubMedGoogle Scholar
  348. Premont RT, Gainetdinov RR (2007) Physiological roles of G protein–coupled receptor kinases and arrestins. Annu Rev Physiol 69:511–534.  https://doi.org/10.1146/annurev.physiol.69.022405.154731 CrossRefPubMedGoogle Scholar
  349. Premont RT, Inglese J, Lefkowitz RJ (1995) Protein kinases that phosphorylate activated G protein-coupled receptors. FASEB J 9:175–182CrossRefPubMedGoogle Scholar
  350. Puig S, Noble F, Benturquia N (2012) Short-and long-lasting behavioral and neurochemical adaptations: relationship with patterns of cocaine administration and expectation of drug effects in rats. Transl Psychiatry 2:e175CrossRefPubMedPubMedCentralGoogle Scholar
  351. Qu S, Ondo WG, Zhang X et al (2006) Projections of diencephalic dopamine neurons into the spinal cord in mice. Exp brain Res 168:152–156CrossRefPubMedGoogle Scholar
  352. Quan W, Kim JH, Albert PR et al (2008) Roles of G protein and β-arrestin in dopamine D2 receptor-mediated ERK activation. Biochem Biophys Res Commun 377:705–709.  https://doi.org/10.1016/j.bbrc.2008.10.044 CrossRefPubMedGoogle Scholar
  353. Rajagopal S, Shenoy SK (2018) GPCR desensitization: acute and prolonged phases. Cell Signal 41:9–16.  https://doi.org/10.1016/j.cellsig.2017.01.024 CrossRefPubMedGoogle Scholar
  354. Ralph RJ, Paulus MP, Fumagalli F et al (2001) Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J Neurosci 21:305–313CrossRefPubMedGoogle Scholar
  355. Rashid AJ, So CH, Kong MMC et al (2007) D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci 104:654–659.  https://doi.org/10.1073/pnas.0604049104 CrossRefPubMedGoogle Scholar
  356. Reitz C, Mayeux R (2014) Alzheimer disease: epidemiology, diagnostic criteria, rist factors and biomarkers. Biochem Pharmacol 88:640–651.  https://doi.org/10.1016/j.bcp.2013.12.024.Alzheimer CrossRefPubMedPubMedCentralGoogle Scholar
  357. Revel FG, Moreau J-L, Gainetdinov RR et al (2011) TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci 108:8485–8490CrossRefPubMedGoogle Scholar
  358. Rey E, Hernández-Diáz FJ, Abreu P et al (2001) Dopamine induces intracellular Ca2+ signals mediated by alpha1B-adrenoceptors in rat pineal cells. Eur J Pharmacol 430:9–17CrossRefPubMedGoogle Scholar
  359. Robbins TW, Everitt BJ (1996) Neurobehavioural mechanisms of reward and motivation. Curr Opin Neurobiol 6:228–236CrossRefPubMedGoogle Scholar
  360. Romano N, Yip SH, Hodson DJ et al (2013) Plasticity of hypothalamic dopamine neurons during lactation results in dissociation of electrical activity and release. J Neurosci 33:4424–4433.  https://doi.org/10.1523/JNEUROSCI.4415-12.2013 CrossRefPubMedPubMedCentralGoogle Scholar
  361. Roos RAC (2010) Huntington’s disease: a clinical review. Orphanet J Rare Dis 5:40CrossRefPubMedPubMedCentralGoogle Scholar
  362. Ross CA, Margolis RL, Reading SAJ et al (2006) Neurobiology of schizophrenia. Neuron 52:139–153CrossRefPubMedGoogle Scholar
  363. Rossi M, Fasciani I, Marampon F et al (2017) The first negative allosteric modulator for dopamine D 2 and D 3 receptors, SB269652 may lead to a new generation of antipsychotic drugs. Mol Pharmacol 91:586–594.  https://doi.org/10.1124/mol.116.107607 CrossRefPubMedPubMedCentralGoogle Scholar
  364. Sahin B, Hawasli AH, Greene RW et al (2008) Negative regulation of cyclin-dependent kinase 5 targets by protein kinase C. Eur J Pharmacol 581:270–275.  https://doi.org/10.1016/j.ejphar.2007.11.061 CrossRefPubMedPubMedCentralGoogle Scholar
  365. Sahu A, Tyeryar KR, Vongtau HO et al (2009) D5 dopamine receptors are required for dopaminergic activation of phospholipase C. Mol Pharmacol 75:447–453CrossRefPubMedGoogle Scholar
  366. Salamone JD, Correa M (2012) The mysterious motivational functions of mesolimbic dopamine. Neuron 76:470–485CrossRefPubMedPubMedCentralGoogle Scholar
  367. Sams-Dodd F (1998) Effects of dopamine agonists and antagonists on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Psychopharmacology 135:182–193CrossRefPubMedGoogle Scholar
  368. Savasta M, Dubois A, Scatton B (1986) Autoradiographic localization of D1 dopamine receptors in the rat brain with [3H]SCH 23390. Brain Res 375:291–301CrossRefPubMedGoogle Scholar
  369. Scheid M, Woodgett J (2001) PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2:760–768.  https://doi.org/10.1038/35096067 CrossRefPubMedGoogle Scholar
  370. Schmidt MJ, Mirnics K (2015) Neurodevelopment, GABA system dysfunction, and schizophrenia. Neuropsychopharmacology 40:190CrossRefPubMedGoogle Scholar
  371. Schrag A, Ben-Shlomo Y, Quinn NP (2000) Cross sectional prevalence survey of idiopathic Parkinson’s disease and Parkinsonism in London. Bmj 321:21–22CrossRefPubMedPubMedCentralGoogle Scholar
  372. Schultz W (1998) Predictive reward signal of dopamine neurons. J Neurophysiol 80:1–27CrossRefPubMedGoogle Scholar
  373. Sedaghat K, Nantel M-F, Ginsberg S et al (2006) Molecular characterization of dopamine D2 receptor isoforms tagged with green fluorescent protein. Mol Biotechnol 34:1–14.  https://doi.org/10.1385/MB:34:1:1 CrossRefPubMedGoogle Scholar
  374. Seeman P, Chau-Wong M, Tedesco J, Wong K (1975) Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci 72:4376–4380.  https://doi.org/10.1073/pnas.72.11.4376 CrossRefPubMedGoogle Scholar
  375. Seeman P, Weinshenker D, Quirion R et al (2005) Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci 102:3513–3518.  https://doi.org/10.1073/pnas.0409766102 CrossRefPubMedGoogle Scholar
  376. Seeman P, Ko F, Jack E et al (2007) Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in postmortem schizophrenia brain. Synapse 61:303–309.  https://doi.org/10.1002/syn.20368 CrossRefPubMedGoogle Scholar
  377. Segura-Aguilar J, Huenchuguala S (2018) Aminochrome induces irreversible mitochondrial dysfunction by inducing autophagy dysfunction in Parkinson’s disease. Front Neurosci 12:106CrossRefPubMedPubMedCentralGoogle Scholar
  378. Segura-Aguilar J, Paris I, Munoz P et al (2014) Protective and toxic roles of dopamine in Parkinson’s disease. J Neurochem 129:898–915.  https://doi.org/10.1111/jnc.12686 CrossRefPubMedGoogle Scholar
  379. Shaywitz BA, Yager RD, Klopper JH (1976) Selective brain dopamine depletion in developing rats: an experimental model of minimal brain dysfunction. Science 191:305–308CrossRefPubMedGoogle Scholar
  380. Shioda N (2017) Dopamine D2L receptor-interacting proteins regulate dopaminergic signaling. J Pharmacol Sci 135:51–54.  https://doi.org/10.1016/j.jphs.2017.10.002 CrossRefGoogle Scholar
  381. Silvano E, Millan MJ, Mannoury C et al (2010) The tetrahydroisoquinoline derivative SB269,652 Is an allosteric antagonist at dopamine D3 and D2 receptors. Mol Pharmacol 78:925–934.  https://doi.org/10.1124/mol.110.065755 CrossRefPubMedPubMedCentralGoogle Scholar
  382. Simon V, Czobor P, Bálint S et al (2009) Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 194:204–211CrossRefPubMedGoogle Scholar
  383. Skagerberg G, Björklund A, Lindvall O, Schmidt RH (1982) Origin and termination of the diencephalo-spinal dopamine system in the rat. Brain Res Bull 9:237–244CrossRefPubMedGoogle Scholar
  384. So CH, Varghese G, Curley KJ et al (2005) D1 and D2 dopamine receptors form heterooligomers and cointernalize after selective activation of either receptor. Mol Pharmacol 68:568–578.  https://doi.org/10.1124/mol.105.012229.the CrossRefPubMedGoogle Scholar
  385. So CH, Verma V, Alijaniaram M et al (2009) Calcium signaling by dopamine D5 receptor and D5-D2 receptor hetero-oligomers occurs by a mechanism distinct from that for dopamine D1-D2 receptor hetero-oligomers. Mol Pharmacol 75:843–854.  https://doi.org/10.1124/mol.108.051805 CrossRefPubMedPubMedCentralGoogle Scholar
  386. Sourkes TL (2009) The discovery of neurotransmitters, and applications to neurology. Handb Clin Neurol 95:869–883CrossRefGoogle Scholar
  387. Spector S, Sjoerdsma A, Udenfriend S (1965) Blockade of endogenous norepinephrine synthesis by $α$-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. J Pharmacol Exp Ther 147:86–95PubMedGoogle Scholar
  388. Spillantini MG, Schmidt ML, Lee VM-Y et al (1997) α-Synuclein in Lewy bodies. Nature 388:839CrossRefPubMedGoogle Scholar
  389. Stahl SM (1985) Platelets as pharmacologic models for the receptors and biochemistry of monoaminergic neurons. In: The platelets: physiology and pharmacology. Academic Press, New York, pp 307–335Google Scholar
  390. Starke K (2014) History of catecholamine research. Chem Immunol Allergy 100:288–301CrossRefPubMedGoogle Scholar
  391. Stefani A, Pierantozzi M, Olivola E et al (2017) Homovanillic acid in CSF of mild stage Parkinson’s disease patients correlates with motor impairment. Neurochem Int 105:58–63CrossRefPubMedGoogle Scholar
  392. Steinhardt RA, Bi G, Alderton JM (1994) Cell membrane resealing by a vesicular mechanism similar to neurotransmitter release. Science 263:390–393CrossRefPubMedGoogle Scholar
  393. Stephan KE, Friston KJ, Frith CD (2009) Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr Bull 35:509–527CrossRefPubMedPubMedCentralGoogle Scholar
  394. Stern JM, Taylor LA (1991) Haloperidol inhibits maternal retrieval and licking, but enhances nursing behavior and litter weight gains in lactating rats. J Neuroendocrinol 3:591–596CrossRefPubMedGoogle Scholar
  395. Stinus L, Herman JP, Le Moal M (1982) GABAergic mechanisms within the ventral tegmental area: involvement of dopaminergic (A 10) and non-dopaminergic neurones. Psychopharmacology 77:186–192CrossRefPubMedGoogle Scholar
  396. Stipanovich A, Valjent E, Matamales M et al (2008) A phosphatase cascade by which rewarding stimuli control nucleosomal response. Nature 453:879–884.  https://doi.org/10.1038/nature06994 CrossRefPubMedPubMedCentralGoogle Scholar
  397. Stokes AH, Hastings TG, Vrana KE (1999) Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 55:659–665CrossRefPubMedGoogle Scholar
  398. Stolzenberg DS, Zhang KY, Luskin K et al (2010) Dopamine D1 receptor activation of adenylyl cyclase, not phospholipase C, in the nucleus accumbens promotes maternal behavior onset in rats. Horm Behav 57:96–104.  https://doi.org/10.1016/j.yhbeh.2009.09.014 CrossRefPubMedGoogle Scholar
  399. Stryker S (1925) Encephalitis lethargica—the behavior residuals. Train Sch Bull (Vinel) 22:152–157Google Scholar
  400. Surmeier DJ, Ding J, Day M et al (2007) D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30:228–235CrossRefPubMedGoogle Scholar
  401. Svenningsson P, Nishi A, Fisone G et al (2004) DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 44:269–296.  https://doi.org/10.1146/annurev.pharmtox.44.101802.121415 CrossRefPubMedGoogle Scholar
  402. Swift JL, Godin AG, Doré K et al (2011) Quantification of receptor tyrosine kinase transactivation through direct dimerization and surface density measurements in single cells. Proc Natl Acad Sci USA 108:7016–7021.  https://doi.org/10.1073/pnas.1018280108 CrossRefPubMedGoogle Scholar
  403. Takano H, Cancel G, Ikeuchi T et al (1998) Close associations between prevalences of dominantly inherited spinocerebellar ataxias with CAG-repeat expansions and frequencies of large normal CAG alleles in Japanese and Caucasian populations. Am J Hum Genet 63:1060–1066CrossRefPubMedPubMedCentralGoogle Scholar
  404. Tan ML, Basu D, Kwiecien JM et al (2013) Preclinical pharmacokinetic and toxicological evaluation of MIF-1 peptidomimetic, PAOPA: Examining the pharmacology of a selective dopamine D2 receptor allosteric modulator for the treatment of schizophrenia. Peptides 42:89–96.  https://doi.org/10.1016/j.peptides.2013.02.004 CrossRefPubMedGoogle Scholar
  405. Tanda G, Frau R, Di Chiara G (1995) Local 5HT 3 receptors mediate fluoxetine but not desipramine-induced increase of extracellular dopamine in the prefrontal cortex. Psychopharmacology 119:15–19CrossRefPubMedGoogle Scholar
  406. Tang T-S, Chen X, Liu J, Bezprozvanny I (2007) Dopaminergic signaling and striatal neurodegeneration in Huntington’s disease. J Neurosci 27:7899–7910CrossRefPubMedPubMedCentralGoogle Scholar
  407. Thomas GM, Huganir RL (2004) MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 5:173–183.  https://doi.org/10.1038/nrn1346 CrossRefPubMedGoogle Scholar
  408. Tiberi M, Nash SR, Bertrand L et al (1996) Differential regulation of dopamine D1A receptor responsiveness by various G protein-coupled receptor kinases. J Biol Chem 271:3771–3778.  https://doi.org/10.1074/jbc.271.7.3771 CrossRefPubMedGoogle Scholar
  409. Trincavelli ML, Daniele S, Orlandini E et al (2012) A new D2 dopamine receptor agonist allosterically modulates A(2A) adenosine receptor signalling by interacting with the A(2A)/D2 receptor heteromer. Cell Signal 24:951–960.  https://doi.org/10.1016/j.cellsig.2011.12.018 CrossRefPubMedGoogle Scholar
  410. Tritsch NX, Sabatini BL (2012) Dopaminergic modulation of synaptic transmission in cortex and striatum. Neuron 76:33–50.  https://doi.org/10.1016/j.neuron.2012.09.023 CrossRefPubMedPubMedCentralGoogle Scholar
  411. Udenfriend S, Wyngaarden JB (1956) Precursors of adrenal epinephrine and norepinephrine in vivo. Biochim Biophys Acta 20:48–52CrossRefPubMedGoogle Scholar
  412. Ugi S, Imamura T, Maegawa H et al (2004) Protein phosphatase 2A negatively regulates insulin’s metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol 24:8778–8789.  https://doi.org/10.1128/MCB.24.19.8778-8789.2004 CrossRefPubMedPubMedCentralGoogle Scholar
  413. Undie AS, Weinstock J, Sarau HM, Friedman E (1994) Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J Neurochem 62:2045–2048.  https://doi.org/10.1046/j.1471-4159.1994.62052045.x CrossRefPubMedGoogle Scholar
  414. Urs NM, Peterson SM, Caron MG (2017) New concepts in dopamine D2 receptor biased signaling and implications for schizophrenia therapy. Biol Psychiatry 81:78–85.  https://doi.org/10.1016/j.biopsych.2016.10.011 CrossRefGoogle Scholar
  415. Valentini V, Cacciapaglia F, Frau R, Di Chiara G (2006) Differential alpha2-mediated inhibition of dopamine and noradrenaline release in the parietal and occipital cortex following noradrenaline transporter blockade. J Neurochem 98:113–121CrossRefPubMedGoogle Scholar
  416. Valjent E, Corvol JC, Pages C et al (2000) Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties. J Neurosci 20:8701–8709 doi: 20/23/8701 [pii]CrossRefPubMedGoogle Scholar
  417. Valjent E, Pascoli V, Svenningsson P et al (2005) Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci 102:491–496.  https://doi.org/10.1073/pnas.0408305102 CrossRefPubMedGoogle Scholar
  418. Vallone D, Picetti R, Borrelli E (2000) Structure and function of dopamine receptors. Neurosci Biobehav Rev 24:125–132CrossRefPubMedGoogle Scholar
  419. Van Tol HH, Bunzow JR, Guan HC et al (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610–614.  https://doi.org/10.1038/350610a0 CrossRefPubMedGoogle Scholar
  420. Venton BJ, Zhang H, Garris PA et al (2003) Real-time decoding of dopamine concentration changes in the caudate–putamen during tonic and phasic firing. J Neurochem 87:1284–1295.  https://doi.org/10.1046/j.1471-4159.2003.02109.x CrossRefPubMedGoogle Scholar
  421. Veselinović T, Paulzen M, Gründer G (2013) Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Expert Rev Neurother 13:1141–1159.  https://doi.org/10.1586/14737175.2013.853448 CrossRefPubMedGoogle Scholar
  422. Viggiano D, Grammatikopoulos G, Sadile AG (2002) A morphometric evidence for a hyperfunctioning mesolimbic system in an animal model of ADHD. Behav Brain Res 130:181–189CrossRefPubMedGoogle Scholar
  423. Volkow ND, Fowler JS, Wang GJ et al (2009) Imaging dopamine’s role in drug abuse and addiction. Neuropharmacology 56:3–8CrossRefPubMedGoogle Scholar
  424. von Euler U (1946) A Specific Sympathomimetic Ergone in Adrenergic Nerve Fibres (Sympathin) and its Relations to Adrenaline and Nor-Adrenaline. Acta Physiol Scand 12:73–97.  https://doi.org/10.1111/j.1748-1716.1946.tb00368.x doiCrossRefGoogle Scholar
  425. Voogt JL, Lee Y, Yang S, Arbogast L (2001) Regulation of prolactin secretion during pregnancy and lactation. Prog Brain Res 133:173–185CrossRefPubMedGoogle Scholar
  426. Walaas SI, Aswad DW, Greengard P (1983) A dopamine-and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions. Nature 301:69CrossRefPubMedGoogle Scholar
  427. Walker FO (2007) Huntington’s disease. Lancet 369:218–228CrossRefPubMedGoogle Scholar
  428. Wamsley JK, Gehlert DR, Filloux FM, Dawson TM (1989) Comparison of the distribution of D-1 and D-2 dopamine receptors in the rat brain. J Chem Neuroanat 2:119–137PubMedGoogle Scholar
  429. Wang G-J, Volkow ND, Logan J et al (2001) Brain dopamine and obesity. Lancet 357:354–357CrossRefPubMedGoogle Scholar
  430. Wang H, Farhan M, Xu J et al (2017) The involvement of darpp-32 in the pathophysiology of schizophrenia. Oncotarget 8:53791PubMedPubMedCentralGoogle Scholar
  431. Watabe-Uchida M, Zhu L, Ogawa SK et al (2012) Whole-brain mapping of direct inputs to midbrain dopamine neurons. Neuron 74:858–873CrossRefPubMedGoogle Scholar
  432. Wauquier A, Rolls ET (1976) Brain-stimulation reward. North-Holland, AmsterdamGoogle Scholar
  433. Weinshilboum RM, Thoa NB, Johnson DG et al (1971) Proportional release of norepinephrine and dopamine-$β$-hydroxylase from sympathetic nerves. Science 174:1349–1351CrossRefPubMedGoogle Scholar
  434. Welsh GI, Hall D, Warnes A et al (1998) Activation of microtubule-associated protein kinase (Erk) and p70 S6 kinase by D2 dopamine receptors. J Neurochem 70:2139–2146CrossRefPubMedGoogle Scholar
  435. Werhahn KJ, Kunesch E, Noachtar S et al (1999) Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J Physiol 517:591–597CrossRefPubMedPubMedCentralGoogle Scholar
  436. Whitehouse PJ, Martino AM, Antuono PG et al (1986) Nicotinic acetylcholine binding sites in Alzheimer’s disease. Brain Res 371:146–151CrossRefPubMedGoogle Scholar
  437. Willems JL, Buylaert WA, Lefebvre RA, Bogaert MG (1985) Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacol Rev 37:165–216PubMedGoogle Scholar
  438. Williams-Gray CH, Worth PF (2016) Parkinson’s disease. Med (United Kingdom) 44:542–546.  https://doi.org/10.1016/j.mpmed.2016.06.001 CrossRefGoogle Scholar
  439. Winkelman JW (1999) The evoked heart rate response to periodic leg movements of sleep. Sleep 22:575–580CrossRefPubMedGoogle Scholar
  440. Wise RA (2009) Roles for nigrostriatal not just mesocorticolimbic dopamine in reward and addiction. Trends Neurosci 32:517–524CrossRefPubMedPubMedCentralGoogle Scholar
  441. Woodard GE, Jardín I, Berna-Erro A et al (2015) Regulators of G-protein-signaling proteins: negative modulators of G-protein-coupled receptor signaling. Int Rev Cell Mol Biol 317:97–183.  https://doi.org/10.1016/bs.ircmb.2015.02.001 CrossRefPubMedGoogle Scholar
  442. Wright HH, Still CN, Abramson RK (1981) Huntington’s disease in black kindreds in South Carolina. Arch Neurol 38:412–414CrossRefPubMedGoogle Scholar
  443. Wurtman RJ, Hefti F, Melamed E (1980) Precursor control of neurotransmitter synthesis. Pharmacol Rev 32:315–335PubMedGoogle Scholar
  444. Xie Z, Miller GM (2007) Trace amine-associated receptor 1 is a modulator of the dopamine transporter. J Pharmacol Exp Ther 321:128–136CrossRefPubMedGoogle Scholar
  445. Xu K, Näveri L, Frerichs KU et al (1993) Extracellular catecholamine levels in rat hippocampus after a selective alpha-2 adrenoceptor antagonist or a selective dopamine uptake inhibitor: evidence for dopamine release from local dopaminergic nerve terminals. J Pharmacol Exp Ther 267:211–217PubMedGoogle Scholar
  446. Xu W, Wang X, Tocker AM et al (2017) Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists. ACS Chem Neurosci 8:486–500.  https://doi.org/10.1021/acschemneuro.6b00221 CrossRefPubMedGoogle Scholar
  447. Yan Z, Song WJ, Surmeier J (1997) D2 dopamine receptors reduce N-type Ca2+ currents in rat neostriatal cholinergic interneurons through a membrane-delimited, protein-kinase-C-insensitive pathway. J Neurophysiol 77:1003–1015.  https://doi.org/10.1152/jn.1997.77.2.1003 CrossRefPubMedGoogle Scholar
  448. Yang LI, Wang Y-F, Li JUN, Faraone SV (2004) Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry 43:1154–1158CrossRefPubMedGoogle Scholar
  449. Yokoyama C, Okamura H, Nakajima T et al (1994) Autoradiographic distribution of [3H]YM-09151-2, a high-affinity and selective antagonist ligand for the dopamine D2 receptor group, in the rat brain and spinal cord. J Comp Neurol 344:121–136.  https://doi.org/10.1002/cne.903440109 CrossRefPubMedGoogle Scholar
  450. Yujnovsky I, Hirayama J, Doi M et al (2006) Signaling mediated by the dopamine D2 receptor potentiates circadian regulation by CLOCK:BMAL1. Proc Natl Acad Sci 103:6386–6391.  https://doi.org/10.1073/pnas.0510691103 CrossRefPubMedGoogle Scholar
  451. Zhang W, Klimek V, Farley JT et al (1999) alpha-2C adrenoceptors inhibit adenylyl cyclase in mouse striatum: potential activation by dopamine. J Pharmacol Exp Ther 289:1286–1292PubMedGoogle Scholar
  452. Zhang W-P, Ouyang M, Thomas SA (2004) Potency of catecholamines and other L-tyrosine derivatives at the cloned mouse adrenergic receptors. Neuropharmacology 47:438–449CrossRefPubMedGoogle Scholar
  453. Zheng W, Zeng Z, Bhardwaj SK et al (2013) Lithium normalizes amphetamine-induced changes in striatal FoxO1 phosphorylation and behaviors in rats. Neuroreport 24:560–565CrossRefPubMedGoogle Scholar
  454. Zion IZB, Tessler R, Cohen L et al (2006) Polymorphisms in the dopamine D4 receptor gene (DRD4) contribute to individual differences in human sexual behavior: desire, arousal and sexual function. Mol Psychiatry 11:782CrossRefPubMedGoogle Scholar
  455. Zucchi R, Chiellini G, Scanlan TS, Grandy DK (2006) Trace amine-associated receptors and their ligands. Br J Pharmacol 149:967–978CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Laboratory of Chemical Neuroanatomy, Department of Anatomy, Institute of Biomedical SciencesUniversity of São Paulo (USP)São PauloBrazil
  2. 2.Center for Translational NeuroscienceSanford Burnham Prebys (SBP) Medical Discovery InstituteLa JollaUSA
  3. 3.Center for Neuroscience and Behavior, Institute of PsychologyUSPSão PauloBrazil

Personalised recommendations